WO2008036162A2 - Gradient wound treatment system and method - Google Patents

Gradient wound treatment system and method Download PDF

Info

Publication number
WO2008036162A2
WO2008036162A2 PCT/US2007/018767 US2007018767W WO2008036162A2 WO 2008036162 A2 WO2008036162 A2 WO 2008036162A2 US 2007018767 W US2007018767 W US 2007018767W WO 2008036162 A2 WO2008036162 A2 WO 2008036162A2
Authority
WO
WIPO (PCT)
Prior art keywords
pressure
wound
sheets
fluid
transducer
Prior art date
Application number
PCT/US2007/018767
Other languages
French (fr)
Other versions
WO2008036162A3 (en
Inventor
David S. Zamierowski
Original Assignee
Kci Licensing, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kci Licensing, Inc. filed Critical Kci Licensing, Inc.
Publication of WO2008036162A2 publication Critical patent/WO2008036162A2/en
Publication of WO2008036162A3 publication Critical patent/WO2008036162A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71Suction drainage systems
    • A61M1/73Suction drainage systems comprising sensors or indicators for physical values
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/91Suction aspects of the dressing
    • A61M1/915Constructional details of the pressure distribution manifold
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/71Suction drainage systems
    • A61M1/77Suction-irrigation systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/90Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
    • A61M1/92Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing with liquid supply means
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00Devices for applying media, e.g. remedies, on the human body

Definitions

  • the present invention relates generally to medical care, and in particular to wound therapy and tissue management systems and methodologies with fluid differentiation.
  • Standard methods in the current practice of wound care require changing the dressing in order to topically add pharmacological agents, which require interval reapplication.
  • Reapplications of pharmacological agents can be minimized or eliminated by using slow-release delivery systems.
  • slow-release delivery systems However, such systems must generally be changed in their entireties in order to change the agents or dosages.
  • Another wound treatment protocol option involves dosing the entire patient. Agents are thereby delivered systemically, i.e. from within the patient, in order to arrive at the wound site, as opposed to other protocols which deliver respective agents externally or topically.
  • systemic medications are generally. administered in relatively high doses in order to provide sufficient concentrations in affected areas and treatment sites. Non-affected tissues and organs remote from the treatment sites thus tend to receive concentrations of medications from which they may not benefit .
  • wound care typically involves absorbing and/or draining wound exudates, blood, serum and other body fluids from the patient.
  • Surgical procedures often create wounds requiring tissue management and fluid drainage.
  • tissue management and fluid drainage procedures are often ineffective in maintaining optimum moisture content for promoting wound healing. Excessive drying, on the one hand, can lead to desiccation, eschar formation and slowing of cell migration. Excessive moisture, on the other hand, can lead to maceration, bacterial overgrowth, tissue breakdown and necrosis.
  • a wound drainage device using a hand-operated suction bulb is shown in the George et al. U.S. Patent No. 4,392,858.
  • Motorized suction pumps can be employed to provide consistent, sub-atmospheric vacuum pressure for maintaining an effective drainage flow.
  • the Richmond et al. U.S. Patents No. 4,655,754 and No. 4,826,494 disclose vacuum wound drainage systems which can be connected to motorized vacuum pumps.
  • Another important objective in designing an effective wound drainage system is to provide an effective interface with the patient. Ideally, the patient interface should accommodate various types of wounds in different stages of recovery for as . broad a range of applications as possible.
  • optimum wound healing generally involves maintaining a sufficient moisture level to avoid desiccation without causing the wound to macerate from excessive moisture.
  • Sufficient moisture levels are required for epithelial cell migration, but excessive moisture can inhibit drying and maturation of the epithelial layer.
  • Pressures should be sufficient for effective drainage without creating excessive negative forces, which could cause pressure necrosis or separate freshly-applied skin grafts.
  • Wound treatment procedures can also include infusing wound sites with liquids to flush contaminants, counter infection, promote healing growth and anesthetize the wound.
  • Prior art fluid delivery systems include a device for treating tissues disclosed in the Svedman U.S. Patent No. 4,382,441; a product and process for establishing a sterile area of skin disclosed in the Gross U.S. Patent No. 3,367,332; and the transdermal infusion device disclosed in the Westin U.S. Patent No.
  • Osmotic and concentration gradients provide an important mechanism for transferring various elements within the scope of the present invention. Such gradients occur naturally in living organisms and involve the movement of solutes from solutions with greater concentrations to solutions with lesser concentrations through semi-permeable membranes. Osmosis is the tendency of solids to pass through semi-permeable membranes into solutions of higher concentrations in order to achieve osmotic equilibrium. Diffusion occurs from an area of higher concentration or partial pressure to an area of lower concentration even without membrane separation. Examples include the diffusion transfer of oxygen from alveoli to capillaries within the lung and the osmotic transfer of toxins and waste within the kidneys from capillaries to tubules and on to the bladder.
  • the systems and methods of the present invention utilize and control osmotic and diffusion gradients to advantage in treating wounds, particularly in connection with the removal of toxins and solution from wound sites by controlling fluids.
  • the control of fluids originates both internally and externally.
  • wound exudates originate internally.
  • External control fluids include sumped air, irrigation, etc.
  • a wound therapy and tissue management system which includes a collector assembly for attachment to a patient, a transfer assembly connected to the collector assembly and a gradient (e.g., negative pressure/vacuum, positive pressure, temperature, oxygen, etc.) source connected by tubing to the transfer assembly.
  • the system is adaptable for use with various dressing assemblies, including multiple layers and components comprising hydrophobia and hydrophilic foam and sponge materials, semi-permeable and impermeable membranes applied as drapes, transfer system conduits and buffers, and tubular connections to pumps.
  • Alternative embodiments of -the system utilize osmotic gradients for controlling transfers and provide various optional configurations with internal and external inputs, installation ports and other components.
  • a fluid differentiation wound therapy and tissue management method which includes steps of shaping and applying a first sponge comprising a first sponge material to a wound area, applying a first drape, shaping and applying a second sponge comprising a second sponge material on top of the first drape and the first sponge, forming a fluid conduit and connecting same to the second sponge and to a buffer for ultimate connection to a vacuum pump.
  • the conduit and the buffer are also draped.
  • Osmotic wound therapy and tissue management methodologies are also disclosed in connection with the present invention. The transfer of fluids and substances such as toxins can be controlled through the application of such methodologies.
  • osmotic transducers are provided for treating wounds by manipulating the gaseous, liquid and solid components in such a way as to create pressure gradients in fluid elements that produce useful fluid flow.
  • Fig. 1 is a block diagram of a vacuum-fixed wound therapy system embodying the present invention.
  • Fig.2 is a perspective view of a composite dressing assembly.
  • Fig.3 is a vertical cross-sectional view of the dressing assembly taken generally along line 3-3 in Fig.2.
  • Fig..4 is an enlarged, fragmentary, cross-sectional view of a composite dressing- comprising a first modified embodiment of the present invention.
  • Fig.5 is a perspective view of a composite dressing comprising a second modified embodiment of the present invention.
  • Fig. 5a is a perspective view of a variation of the embodiment shown in Fig. 5.
  • Fig. 6 is a perspective view of a transfer assembly for a composite dressing comprising a third modified embodiment of the present invention.
  • Fig. 7 is a cross-sectional view of a third modified embodiment composite dressing.
  • Fig. 8 is a perspective view of the third modified embodiment composite dressing.
  • Fig. 9 is a perspective view of a composite dressing comprising a fourth modified embodiment of the present invention.
  • Fig. 10 is a flow diagram of a vacuum-fixed wound, therapy method embodying the present invention.
  • Fig. 11 is an exploded view of a wound treatment system with vacuum, heat and fluid assistance.
  • Fig. 12 is an exploded view of another wound treatment system with vacuum, heat and fluid assistance.
  • Fig. 13 is an exploded view of yet another wound treatment system, with vacuum, heat and fluid assistance.
  • Figs.l4a-d comprise graphs showing the temperature- elevating performance of the wound treatment systems shown in Figs 11-13.
  • Fig. 15 is a block diagram of a wound therapy and tissue management system comprising an eighth alternative embodiment of the present invention.
  • Fig. 16 is a schematic diagram of the eighth alternative embodiment wound therapy and tissue management system.
  • Fig. 17 is a flowchart of a wound and therapy- and tissue management methodology embodying the present invention.
  • Fig. 18 is a block diagram of a wound therapy and tissue management system comprising a ninth alternative by the present invention.
  • Fig. 19 is a diagram showing various phases in a hyperosmolar or air-sump system embodying the present invention.
  • Fig. 20 is a diagram showing various phases in an osmolar or isotonic flush or rinse system embodying the present invention.
  • Fig. 21 is a diagram showing a hypo-osmolar or heavy drape system embodying the present invention.
  • Fig. 22. is a diagram showing a generic model of a gradient wound treatment system.
  • Fig. 23 is a perspective view of an alternative embodiment composite sheet panel system.
  • Fig. 23A is a cross-sectional view thereof, taken generally along line 23A-23A in Fig. 23.
  • Fig. 24 is a perspective view of another alternative embodiment composite sheet panel system.
  • Fig. 24A is a cross-sectional view thereof, taken generally along line 24A-24A in Fig. 24.
  • Fig. 25 is a perspective view of another alternative embodiment composite sheet panel system.
  • Fig. 26 is a perspective view thereof, shown installed in a wound for closing same.
  • Fig. 27 is a perspective view of another alternative embodiment composite sheet panel system.
  • Fig. 28 is a perspective view of another alternative embodiment composite sheet panel system.
  • Fig. 28A is a cross-sectional view thereof, taken generally along line 28A in Fig. 28.
  • Fig. 28B is another cross-sectional view thereof, taken generally along line 28B in Fig. 28.
  • Fig. 29 is a cross-sectional view of another alternative embodiment composite sheet panel system.
  • Fig. 29A is an enlarged, cross-sectional view thereof, taken generally within circle 29A in Fig. 29.
  • Fig. 30 is a cross-sectional view of another alternative embodiment composite sheet panel system.
  • Fig. 31 is a cross-sectional view thereof, shown in a wound for closing same.
  • Fig. 32 is another cross-sectional view thereof, shown in another wound for closing same
  • Fig. 33 is a plan view of another alternative embodiment composite sheet panel system.
  • Fig. 33A is a cross-sectional view thereof.
  • Fig. 34 is a plan view of another alternative embodiment composite sheet panel system.
  • Fig. 34A is a cross-sectional view thereof.
  • Fig. 35 is a cross-sectional view of another alternative embodiment composite sheet panel system.
  • Fig 36 is another cross-sectional view thereof, shown in a compressed, compacted configuration.
  • Fig. 37 is a cross-sectional view of another alternative embodiment composite sheet panel system.
  • Fig. 38 is a cross-sectional view of another alternative embodiment gradient wound treatment system.
  • Fig. 39 is a perspective view of another alternative embodiment composite sheet panel system.
  • Fig. 40 is a cross-sectional view thereof, taken generally along line 40-40 in Fig. 39.
  • Vacuum-fixed Wound Therapy Dressing 3 generally designates a vacuum-fixed wound therapy system for application to a wound 4 on or in a patient 5.
  • the system 2 includes an improved dressing 3.
  • Other components of the system 2 are described in my U.S. Patent No. 6,071,267, which is incorporated herein by reference .
  • the dressing 3 generally includes a collector assembly 6 and a transfer assembly 8 connected to a vacuum source 10.
  • the collector assembly 6 includes a first sponge 12 comprising a hydrophilic material, such as polyvinyl alcohol (PVA) .
  • PVA polyvinyl alcohol
  • the first sponge 12 is cut to generally conform to the size of the wound 4.
  • a first sponge drape 14 is placed over the first sponge 12 and an opening 16 is formed in the drape 14 and is preferably sized smaller than the first sponge 12.
  • the drape 14 encloses acompression chamber 15 containing the first sponge 12.
  • a dry skin, moisture-control zone 17 is formed around the first sponge 12 due to air circulation within the compression chamber 15 and promotes healing.
  • a second sponge 18, preferably comprising a hydrophobic polyurethane ether (PUE) material is sized larger than the first sponge 12, whereby a second sponge overhang 20 extends beyond the perimeter of the first sponge 12.
  • a second sponge drape 22 is placed over the second sponge 18 and includes an opening 24 located along an outer edge 26 of the second sponge 18 for directing the outflow of fluid effluent from the collector assembly 6.
  • the transfer assembly 8 includes a conduit 28, which can comprise the same hydrophobic material as the second sponge 18.
  • the conduit 28 includes an inlet end 30 which is offset in order to overlie the second sponge drape opening 24 along the second sponge outer edge 26.
  • a conduit outlet end 32 mounts a buffer 34, which also preferably comprises the hydrophobic foam and projects outwardly from the conduit 28 and receives a suction tube 36 which is also connected to the vacuum source (e.g., pump) 10.
  • a conduit drape 38 overlies the conduit 28 and includes an opening 40, which receives the buffer 34.
  • a buffer drape 42 includes a first panel 42a and a second panel 42b, which are secured together over the buffer 34 and the suction tube 36 to enclose same.
  • the buffer drape first and second panels 42a, b are mounted on the conduit drape 38 around the opening 40 therein.
  • the hydrophilic first sponge 12 tends to collapse under negative pressure. Therefore, the size of the first sponge 12 is limited and it is preferably mounted inproximity to an edge 26 of the second sponge 18.
  • the second sponge 18 cooperates with the transfer assembly to distribute the negative pressure throughout the hydrophobic second sponge 18 and in turn throughout the first sponge 12.
  • the PVA material comprising the first sponge 12 permits it to compress under a negative pressure gradient.
  • the overlying second sponge 18 tends to distribute the negative pressure gradient relatively evenly across substantially the entire area of the first sponge 12.
  • the PUE composition of the second sponge 18 provides a retriculated latticework or weave which resists compression and includes relatively open passages to facilitate fluid flow.
  • the collector assembly 6 is constructed by first forming the first sponge 12 to generally conform to the wound 4, whereafter the second sponge 18 is formed to provide the overhang 20.
  • the first sponge 12 is covered with the first sponge drape 14, the opening 16 of which is normally sized smaller than the overall area of the first sponge 12.
  • collector assembly 6 construction The functional advantages of the collector assembly 6 construction include optimizing compression and fixation and edema control at the wound edge while maximizing the air-induced drying of the intact skin in the dry skin zone 17.
  • collector assemblies and transfer assemblies can be mixed and configured in a wide variety of arrangements to accommodate various patient conditions. For example, multiple transfer assemblies 8 can be connected to a single collector assembly 6 and vice versa.
  • a wound dressing 53 comprising a first modified embodiment of the present invention is shown in Fig.4 and includes a liner 54 between the wound 4 and a first sponge 56, which can comprise a hydrophilic or hydrophobic material.
  • the liner 54 passes fluid, but partially isolates and shields the wound tissue from the first sponge 56 to prevent the formation of spicules penetrating the open-passage first sponge 56.
  • the liner 54 thus permits the first sponge 56 to comprise hydrophobic (e.g., PUE) material, even when spicule penetration is not desired.
  • FIG. 5 A wound dressing comprising a second modified embodiment of the present invention is shown in Fig. 5 and generally comprises a collector assembly 106 and a transfer assembly 108.
  • the collector assembly 106 can be similar to the collector assembly 6 with a suitable composite construction.
  • the transfer assembly 108 comprises an elbow connector 110 placed on top of a second sponge drape 112 covering the second sponge 114.
  • the elbow connector 110 mounts the distal end 116 of a suction tube 118, which is also connected to a vacuum source 10.
  • a first sponge drape 120 is placed over a first, hydrophilic sponge 122 and includes a central opening 123 communicating with the second sponge 114.
  • Fig. 5a shows an interface device 102a comprising a variation of the construction of the wound dressing 102.
  • the device 102a utilizes a flexible, bellows-type tubing section 1 10a in place of the elbow connector 110 described above.
  • a needle-free, leur lock hub 124a is mounted on the end of the tubing section 1 10a and functions as an injection port.
  • the sponge 122 can be omitted from the dressing 102a whereby same can be used as a fluid inlet or outlet in various applications and on many different configurations of dressings.
  • a fluid differentiating wound dressing 202 comprising a third modified embodiment of the present invention is shown in Figs.6-8 and generally comprises a transfer assembly 204 (Fig.6) adapted for mounting on a collector assembly 206 as shown in Fig.7.
  • the transfer assembly 204 comprises a sponge material buffer 208 which can comprise, for example, polyurethane ether (PUE) .
  • the buffer 208 is encased in first and second drape panels 210, 212 with wings 210a, 212a respectively extending in opposite directions from the buffer 208.
  • the wings 210a, 212a have an adhesive layer 214, which is covered by a removable backing sheet 216 prior to installation.
  • Tab strips 218 are provided at the ends of the drape wings 210a, 212a.
  • the tab strips 218 are attached by perforated lines 220 for easy removal upon installation.
  • the suction tube 36 is embedded in the buffer 8 and extends outwardly from the transfer assembly 204 from between the first and second drape panels 210, 212.
  • An optional leur-lock hub to 13 is mounted on the end of the tube 36 for injection port applications.
  • the transfer assembly 204 is adapted for mounting on a collector assembly 206 (Fig.7), which is similar to the collector assembly 6 described above.
  • An opening 224 is formed in a second drape 222 which overlies a second sponge 218.
  • the adhesive layer 214 on the drape panel wings 210a, 212a secures the transfer assembly 204 in place whereby the buffer 208 is in communication with the second sponge 218 through the opening 224.
  • An optional first sponge 212 can be placed on the wound 4 and covered with drape 214 with an opening 216 formed therein.
  • the dressing 202 can also be utilized with a single sponge for the collector assembly 206.
  • Fig. 8 shows an application of the dressing 202 wherein the transfer assembly 204 is mounted over a medial or interior portion 218a of the second sponge 218.
  • a first end 208a of the buffer 208 can be folded substantially flat on top of the second drape which overlies the second sponge 18.
  • a second end 208b of the buffer 208 extends outwardly from the collector assembly 206.
  • the buffer 208 can flex in response to pulling forces tugging on the suction tube 236.
  • the dressing 202 as shown in Fig. 8 is wrapped with drape strips 222, which are adapted for encircling an extremity of a patient.
  • the buffer first end 208a is secured by a drape strip 222 as shown.
  • the drape strips 222 can be utilized for applying a compressive force to the dressing 202. In operation, evacuating the dressing 202 causes portions of it to shrink, compress and collapse under the pressure gradient, thus providing a visual indication of its performance .
  • Fig. 9 shows a fluid differentiating wound dressing 302 comprising a fourth modified embodiment of the present invention.
  • the dressing 302 includes a collector assembly 304 and a transfer assembly 306 .
  • the collector assembly 304 includes first and second sponges 308, 310.
  • the first sponge 308 is mounted on the wound and can comprise, for example, a hydrophilic foam material as described above.
  • the second sponge 310 can be mounted directly on the first sponge 308 (optionally separated by a drape) and can receive a tube 312 connected to a vacuum source.
  • the second sponge 310 can include an overhang 313 extending beyond the first sponge 308 for providing a compression chamber 315 as described above.
  • a drape 314 is placed over the collector assembly 304 and the tube 312. The drape 314 is folded over the tube 312 whereby same is spaced outwardly from the skin, thus providing an effective, fluid-tight seal around the tube 312.
  • Fig. 10 shows a wound therapy method embodying the present invention.
  • the method can be performed with one or more of the systems discussed above, including the vacuum-fixed dressings 3, 53, 102, 202 and 302.
  • the method can also be performed with a wide variety of variations on the systems and dressings disclosed above .
  • Fig. 11 shows a wound therapy and tissue management system 402 comprising a fifth modified embodiment of the present invention.
  • the system 402 includes a dressing 404 placed on a wound 406. Any of the dressing systems discussed above can be utilized.
  • the enclosure 414 is placed over the wound site 406 and includes an opening 416 extending therethrough and adapted for receiving a warming card 418 in covering relation thereover.
  • the warming card 418 is operationally connected to 1 a temperature control unit 420.
  • a vacuum assisted closure unit 408 is fluidically connected to the enclosure 414 by a suitable suction tube and in turn is connected to a power source 410.
  • the warming card 418 is heated and raises the temperature within the enclosure 414 to promote healing.
  • the vacuum assisted closure 408 functions as described above to remove effluent and to promote healing in cooperation with the warming card 418. Warming cards and other components for use in connection with this embodiment of the invention are available from Augustine Medical Products, Inc.
  • FIG. 12 shows a wound therapy and tissue management system 502 comprising a sixth modified embodiment of the present invention.
  • the system 502 is similar to the system 402 described above.
  • a composite dressing 504 is comprised of first and second layers 506, 508.
  • a fluid source 518 communicates with a temperature control and pump unit 514 and provides influx to the system 502.
  • Fig. 13 shows a wound therapy and tissue management system 602 comprising a seventh modified embodiment of the present invention.
  • the system 602 is similar to the systems 402 and 502 described above.
  • a transfer element 604 is covered by a drape 620, which mounts a film 616 adapted for receiving a warming card 618.
  • Figs. 14a-14d shows the results of tests performed with the dressing systems and methodologies discussed above and variations thereon.
  • Fig. 14a shows system performance (time and temperature) with a dry PUE hydrophobic sponge material.
  • Fig. 14b shows system performance with a wet PVA hydrophilic sponge material.
  • Fig. 14c shows performance with an irrigated PUE hydrophobic sponge material with a warm-up plate (heating card) and a cover.
  • Fig. 14d shows system performance with both PUE hydrophobic sponge material and PVA hydrophilic sponge material.
  • Figs. 15 and 16 show a wound therapy and tissue management system 702 comprising an eighth modified embodiment of the present invention.
  • the system 702 is shown schematically in Fig. 15 and consists of inputs 704, the patient 706, outputs 708 and a feedback loop 710.
  • the inputs 704 can comprise virtually any matter or energy deemed appropriate for the treatment protocol by the health-care practitioner. For example, various irrigation fluids, growth factors, antibiotics, anesthetics, etc. can be input to the patient 706. Still further, the inputs can comprise various forces and energy forms whereby a matter/energy gradient is established with respect to the patient 706.
  • negative pressure from a suitable vacuum source can be an input for creating a negative pressure gradient across the system.
  • positive pressure from a suitable fluid pump can be input to establish a positive pressure gradient across the system.
  • Other forces can provide electromagnetic, electrical, mechanical and thermal gradients.
  • the system 702 monitors performance of the patient 706 and controls the inputs 704 interactively in response thereto. Parameters which could be monitored for feedback purposes included moisture levels, temperature, bacteria levels, fluid pressure, etc. The presence or absence of particular elements and compounds can also be sensed, monitored and acted upon. For example, is widely known that oxygen is an important factor in wound healing.
  • oxygen level within the enclosed, wound site environment can be monitored and the oxygen levels therein either increased or decreased as necessary to promote healing.
  • Other controllable parameters include the pH factor and the moisture concentration of the wound environment.
  • Various suitable monitoring means can be employed, including electronic sensors, visual indicators, color-change substances, etc.
  • Fig. 16 is a block diagram of the system 702, showing the components thereof in greater detail.
  • a programmable controller 712 can be preprogrammed to operate the system according to predetermined protocols.
  • the controller 712 is connected to and controls the operation of the input source 714 and the gradient source 716.
  • the input source 714 can comprise any suitable matter or energy for input to the system 702, including various fluids, medications, thermal energy, mechanical forces, temperature, etc., as discussed above.
  • the gradient source is likewise unlimited.
  • pressure gradients are particularly suitable for controlling the operation of the system 702 for draining wounds.
  • Other types of gradients include temperature, osmotic, oncotic, pH, oxygen demand, bacteria concentrations, etc., as discussed above.
  • a gradient source 716 can comprise any suitable device for establishing a gradient.
  • a vacuum source can be utilized for creating a negative pressure gradient.
  • a pump can be utilized for creating a positive pressure gradient.
  • a drape 718 is placed in covering relation over a transfer element 720.
  • the drape 718 can comprise any of the film materials discussed above and can be permeable, semi-permeable or impervious.
  • the transfer element 720 includes a first zone 720a with a first set of fluid flow characteristics and a second zone 720b with a second set of fluid flow characteristics.
  • Such fluid flow characteristics can be a function of material, thickness, porosity, permeability, and sponge material attraction to proteins, fat cells and other substances.
  • the zones 720a, b can be formed by providing layers of the material, by providing varying thicknesses, by interspersing a first material within a second material in predetermined configurations, etc.. Still further, the first and • second zones can be formed by subjecting the transfer element 720 to an electromagnetic field.
  • the first and second zones 720a,b can also be formed by varying the density of the transfer element 720, as indicated by the dashed line 732 (Fig. 16) .
  • Line 732 represents compressed material (e.g., foam) along one edge and expanded material in the second zone 720b. Such density gradients can be achieved by compressing the material or by heat-setting same in a manufacturing process. Transfer element 720 edges can also be compressed when the dressing is applied to achieve a desired density gradient. Material thickness can also be utilized to provide a flow coefficient gradient. In this case line 732 could represent a tapering of the transfer element 720 across the first and second zones 720a, 720b.
  • a marbling effect with a material concentration gradient is shown at 733, with greater concentration along an edge and decreasing concentration towards interior portions of the transfer element 720, or vice-versa. Constructing the first and second zones 720a, 720b of different materials with different respective flow coefficients could also achieve a desired flow gradient.
  • Medications and other substances can be applied to the transfer element materials to alter the flow characteristics thereof.
  • Systemic agents 731 can be administered to the patient 726.
  • Fluid 722 can be introduced into the wound site 724 from the inputs 714 and its flow pathways can be controlled by the gradient source 716.
  • sponge materials with different flow characteristics can be configured to direct fluid (either gas or liquid) in predetermined flow patterns through the transfer element 720.
  • Effluent 728 from the patient 726. is withdrawn from the wound site 724 and evacuated to a collection receptacle 730.
  • Fig. 17 shows a flowchart for a wound therapy and tissue management methodology embodying the president mentioned. From Start 804, the method proceeds to Diagnose Patient Condition 806. Based on the diagnosis, a treatment protocols selected.
  • the protocol includes an identification of a gradients to be controlled by the methodology. For example, protocols involving vacuum-assisted wound drainage will generally include a negative pressure gradient. Additional possible gradients are discussed above. It will be appreciated that virtually unlimited combinations of gradients can be formed in the system 702.
  • the timing of the gradient control can be varied as needed to achieve desired treatment results. For example, . collagen production and reepithelialization can be promoted by hyperbaric oxygen treatment procedures, such as alternating elevated and reduced oxygen concentrations . Suction/compressive pressures can also be alternated to stimulate tissue growth.
  • Gradient sources are provided at 810 and can comprise vacuum/suction, fluids, medications, oxygen and various other matter and energy. Gradients can also be formed utilizing energy sources, such as thermal, mechanical force, etc.
  • First and second transfer characteristics are selected at 812, 814 respectively.
  • a transfer element (s) is provided at 816 and includes the transfer characteristics selected at 812, 814.
  • the patient is prepared at 818. Patient preparations can include any suitable medical procedures, such as debriding the wound, etc.
  • the transfer element is applied at 820 and draped at 822.
  • the transfer element is connected to a gradient source at 824 and the gradient is applied at 826.
  • Fluid is transferred through the first transfer element zone at 828 and through the second transfer element zone at 830. It will be appreciated .that such transfer zones can be adapted for directing the fluid along certain pathways to achieve desired results, such as evacuation of exudates.
  • the fluid is differentiated (e.g., liquids, gases or liquids and gases are separated) at 832.
  • the operating parameters are monitored at 834 and the gradient source (s) are adjusted accordingly add 836. Thereafter a "Continue?" decision box 838 is reached. If affirmative, the method returns to Apply Gradient 826 and operation continues with the adjusted gradient parameters. A negative decision at 838 leads to a termination of the procedure (i.e., "End") at 840.
  • Figs. 18-21 show a wound therapy and tissue management system 902 and methodology utilizing a controlled osmotic gradient.
  • a patient 904 includes capillaries 906 which provide fluid, such as serum and blood, to a wound 908. Such fluid passes to the transfer element 910.
  • An air sump control 914 communicates with the transfer element 910 through an air sump conduit 912.
  • a discharge control 918 communicates with the transfer element 910 through a discharge conduit 916.
  • the controls 914, 918 are interactively controlled by a controller 922, which is adapted to receive control input signals.
  • Such input signals can comprise, for example, preprogrammed inputs, feedback signals (Fig. 15) , etc..
  • the input signals can originate at sensors associated with the system 902 and with the patient 904.
  • Such inputs can effectively control the osmotic gradient to achieve desired fluid, solvent and solute (e.g., toxin) transfers.
  • the primary external substance input can comprise relatively dry ambient air. Air movement through the system 902 tends to collect moisture for discharge as water vapor .
  • the system 902 is covered by a drape 920, which can comprise various semi-permeable and impervious materials as required by fluid flow considerations and various applications. For example, an impervious drape 920 tends to block air from the system 902 and permit entry of same only through the air sump control 914.
  • Fig. 19 shows a hyperosmolar or air-sump system.
  • Phase 1 represents a steady-state or increasing-toxin A condition and a concomitant increasing movement of toxin A back into the patient.
  • phase 2 a hyperosmolar solution or air sump is introduced. This gradient draws fluid from the capillaries to replace the fluid moved out of the wound into the transfer element carrying toxin A with it and decreasing movement of toxin A into the patient.
  • warmed irrigating fluid can be introduced into the transfer element in phase 2.
  • the advantages of warming the transfer element and wound site in this manner include vasodilation, increase in cell motility and an increase in phagocytosis. For example, irrigating fluid warmed to approximately 40 degrees centigrade has been shown to remove the inhibitory effect of chronic wound fluid on cell culture motility and proliferation.
  • phase 3 ongoing administration of this gradient continues these fluxes as water vapor is removed and dry air is sumped.
  • phase 4 is results in a new steady-state condition with lower levels of toxin A in the wound (and the patient) and increased fluid and toxin A in the transfer element that is continuously evacuated.
  • Fig. 20 shows an isosmotic or isotonic flush or rinse methodology.
  • phase 1 there is a steady-state (or increasing toxin A level) condition with fluid (liquids) moving out from the wound to the transfer element being replaced by serum exudate from the capillary. Evaporative loss from the transfer element is kept to a minimum by application of a drape material.
  • phase 2 an isomotic rinse is introduced, increasing the fluid content of the transfer element and decreasing the concentration of toxin A, enabling a diffusion of toxin A from the wound into the transfer element.
  • phase 3 as this fluid is withdrawn, it also removes toxin A, enabling a continued diffusion of toxin A put of the wound.
  • phase 4 the resulting condition is fluid equilibrium and decreased concentration of toxin A in the wound. As this situation reverts to phase 1, the flush or rinse is repeated at intervals.
  • Fig. 21 shows a hypo-osmolar or heavy drape system.
  • steady-state conditions generally exist with some evaporative loss of fluid (water vapor) .
  • phase 2 small amounts of hypo-osmolar fluid are introduced, or a cover/drape is placed over the transfer element with a heavy drape completely blocking evaporative loss, thus adding "free water” to the system. This reverses the outward flow of fluid from the wound.
  • phase 3 this increased fluid in the wound allows the total amount of toxin A to also accumulate in the wound.
  • phase 4 this increase of fluid and toxin A in the wound without any egress produces movement of fluid (edema) and toxins (cellulitis) back into the patient and into the lymphatics .
  • Fig. 22 shows a generic, model of an osmotic transducer system 1002 for treating a wound 1004 by manipulating the gaseous, liquid and solid components in such a way as to create pressure gradients in fluid elements that produce useful fluid flow.
  • the system 1002 is shown applied to an exposed tissue layer 1005.
  • a pressure transducer component 1006 can comprise a porous hydrophobic material, such as polyurethane ether (PUE) foam, or a hydrophilic material, such as polyvinyl alcohol (PVA) foam.
  • PUE polyurethane ether
  • PVA polyvinyl alcohol
  • various other materials with suitable fluid mechanics and handling properties can be utilized, including naturally-occurring or man-made materials, or both.
  • the pressure transducing function of the component 1006 involves several different kinds of pressures from different sources, which are generally designated P in Fig. 22.
  • gas components can be changed or gas pressure relative to ambient air can be changed, producing gradients.
  • Osmotic and/or oncotic liquid pressures can be involved in causing patient fluid to flow through the system 1002.
  • Capillary pressure is a function of the spaces in the solids or materials comprising the transducer component 1006.
  • the tissue layer 1005 also functions as a transducer for pressure P.
  • Externally-applied pressure P can originate at a negative pressure source, such as a vacuum pu ⁇ , or at a positive pressure source, such as a fluid pump.
  • the transducer system 1002 includes a base element 1008 generally comprising the transducer component 1006 partly surrounded by a cover 1010.
  • the fluids acted on can be gaseous or liquid. Many applications will involve both.
  • the base element 1008 communicates and interacts with its environment. Gradients are actively established by the containment and manipulation of the base element 1008.
  • the cover or membrane 1010 modulates fluid pressure or flow by its physical properties of rigidity and flexibility, which can resist movement associated with a pressure gradient across the two sides of the cover or membrane 1010 and, conversely, the ability to collapse or change shape as a result of this gradient.
  • Changing fluid pressure and volume modulates osmotic, capillary and atmosphere pressures, thereby changing the shape of the cover 1010.
  • changing the size and/or shape of the cover 1010 can produce fluid gradients by changing solvent volume for osmotic pressure, tube radius for capillary pressure and fluid volume/container volume for atmospheric pressure.
  • the porosity of the cover 1010 to fluids and solutes is another physical property, which affects fluid pressure and/or flow modulation by the cover 1010.
  • cover 1010 porosity can range from porous to semi-permeable to impervious.
  • Semi-permeable covers 1010 are generally selectively capable of passing certain gaseous (vapor) phase elements and are impervious to certain liquid phase substances.
  • Such selective permeability for various sizes of solutes which can be a function of pore size, can be used for selectively creating fluid flow conduits for certain substances with the cover 1010.
  • the transducer component 1006 is located in a central or contained space 1012 generally defined by the cover 1010 and the tissue layer 1005, and can also be designed to manipulate fluid pressure and flow. Selective permeability for various sizes of solutes, which can be a function of pore size, can be used for selectively creating fluid flow conduits for certain substances with the transducer component 1006.
  • the ' space 1012 can contain fluid alone, with or without solutes, or fluid and an engineered solid (e.g. bioengineered cells, beads, etc.) . Fluid gradients for directing flow can be created, controlled and manipulated as a function of osmotic, capillary and atmospheric pressures.
  • Osmotic pressure control can be utilized with gas, liquid (with or without solutes) or both. By adjusting the concentrations of dissolved elements, a gradient can be established across the cover 1010 between the transducer component 1006 and the external environment.
  • Capillary pressure control can involve transducer component 1006 configurations such as screens and three-dimensional meshwork providing channels and passages with predetermined sizes. A gradient can thereby be produced across the cover 1010, and can be engineered to modulate in response to the amount of fluid that is flowing.
  • the transducer component 1006 can comprise, for example, an absorbable meshwork, which swells with liquid absorption whereby the spaces and passages change with exposure to liquid and cause corresponding changes in the capillary pressure gradients.
  • the transducer component 1006 meshwork can be configured to hold more fluid at increased pressures (e.g., changing volume under osmotic pressure), thereby stretching the cover 1010, physically changing the conduit and passage sizes and modulating the pressure gradients and corresponding fluid flow.
  • pressures e.g., changing volume under osmotic pressure
  • Atmospheric pressure can remain constant through volume changes if the cover 1010 is sufficiently flexible -to accommodate such changes.
  • Differential fluid pressures and other gradients can be created and manipulated by selective permeability and rigidity of the cover membrane 1010. Strong osmotic/oncotic pressures can be established across the cover 1010 in order to cause liquid to selectively cross into the transducer 1012.
  • the cover 1010 is less flexible or stretchable, pressures tend to change within the central space 1012. For example, dissolved oxygen may be present in the central space 1012 and may be forced out through the cover 1010 by an increase in pressure. A water removal/oxygen delivery system is thus created.
  • a specific connector conduit portion can be established in the cover 1010 for allowing active (mechanical or otherwise) modulation of atmospheric pressure (both positive and negative) inside the transducer component 1006, with the resultant gradient and fluid flow changes that will result to the other phases and elements in the central space 1012.
  • the ambient atmosphere and environment external to the transducer system 1002 can also be part of the system and controlled in order to achieve various desired performance objectives.
  • the external environment can be ambient, or it may be contained within a larger, secondary enclosure.
  • Connectors or patches, such as the cover connector 1014 can be utilized for fluid and pressure communication to the system 1002 from external sources, e.g. through tubing 1016.
  • Ambient liquids of various constitutions, concentrations and pressures can also comprise the ambient environment, and can be manipulated in order to achieve desired performance. Liquid volumes and concentrations can be sufficiently large for pressures and other characteristics to remain relatively constant contemporaneously with pressure gradient control and manipulation.
  • the tissue layer 1005 also has an interface relationship with the base element 1008.
  • the system 1002 is medically useful in part because of its ability to control fluid flows involving solutes that are medicinal, nutritional and metabolically active.
  • Biological tissue inherently functions as a cover membrane. Therefore, sealing the edges of the cover 1010 to healthy skin around the wound 1004 configures the system with the tissue layer 1005 comprising the lower enclosure, which cooperates with the cover 1010 to enclose the transducer component 1006.
  • steep gradients and rapid fluid flows can be achieved by constructing the layers of the system 1002 in such a way as to move accumulated concentrations of elements away from the base layer interface between the tissue 1005 and the transducer component 1006.
  • Tissue interaction can take the form of fluid absorption, exudation/transudation, exchange (solute/solvent), cellular response, and other physiological interactions.
  • Interconnecting base elements 1008 together inside of an interconnected second space environment attached to tissue can provide a device capable of expansion or contraction to fit multiple fluid flow needs for removal and delivery requirements for medical treatment of tissue of all sizes.
  • the base element 1008 can range in size from gross macroscopic to molecular and nanometer, and tubule passage sizes can correspondingly cover a wide range for achieving desired fluid, pressure, gradient, biologic and other effects. Without limitation on the generality of useful applications of the present invention, it is anticipated that most of the desired fluid effects will occur utilizing passages and matrices in the micron to millimeter range.-
  • Gradients can be formed with various forces and interactions at different locations within the system 1002.
  • 1016 positive and negative pressures associated with external fluid and pressure sources can be formed.
  • the outer surface of the cover 1010 forms an interface with the atmosphere or other environment external to the base element 1008.
  • the inner surface of the cover 1010 forms an interface between the cover and the transducer component 1006.
  • osmotic, oncotic, chemical, biological, thermal and other gradients are formed.
  • a transducer/tissue interface is formed between the transducer component 1006 and the tissue layer 1005.
  • gradients are formed within the tissue layer 1005.
  • FIG. 23 and 23A Another modified embodiment composite sheet panel system 1022 is shown in Figs. 23 and 23A and generally comprises a pair of perforated or semi-permeable sheets 1024 positioned in generally parallel, overlying relation with spot interconnections (e.g., spot welds) 1026, which can be suitably spaced for optimal performance.
  • a pair of manifolds 1028 is provided along edges of the sheets 1024 for fluid introduction into or extraction out of an interstitial space 1030 comprising multiple, interconnected fluid passage pockets.
  • Port assemblies 1032 for inflow and outflow are connected to the manifolds 1028 and can comprise Luer lock connectors, drain cocks, vents, sealing plugs, etc. for connection to the atmosphere or suitable sources of pressure and/or fluids, which can be chosen for particular patient indications.
  • the central space 1030 can expand under positive pressure whereby multiple chambers and passages are formed between the sheets 1024 and the spot interconnections 1026.
  • fluid content to one of the ports 1032 can be dissipated throughout the wound, and fluid drainage can be accomplished through the other port 1032.
  • the spot interconnections 1026 can restrain separation of the sheets 1024, which may be desirable when the central space 1030 is filled with larger volumes of pressurized fluid.
  • the panel system 1022 can comprise various thin, flexible and durable materials, including polyurethane, cellulose, cellophane or rayon. Such materials are preferably chosen for their properties of permeability, i.e.
  • membrane-like behavior for separating types of fluid on each side, and liquid adhesion involving their abilities to adhere to various liquids presented to the sheet 1024 surfaces and surface tension properties.
  • the surfaces can optionally be coated with proteins and other materials affecting liquid adhesion. Hydrophobic and hydrophilic properties are also applicable to membrane-like performance. Additional performance-affecting construction material variables include the thickness and permeability of the sheets 1024. Still further, the size and spacing of the spot interconnections 1026 can vary considerably among systems embodying the present invention. For example, micro-systems with sub-centimeter spacing may be indicated for certain closure procedures, whereas macro systems with interconnections spaced several centimeters apart may be indicated for others.
  • the manifolds 1028 and the ports 1032 can likewise have various sizes, configurations and locations.
  • manifolds 1028 can be located on opposite edges, over-and- under along the same edge or along adjacent edges.
  • the panel system 1022 can be provided as an elongated strip, which can be cut-to-length transversely for custom-fit installations.
  • the cut edges can be taped over or otherwise suitably closed.
  • the ports 1032 can be fabricated with flexible tubing or other suitable materials, and can be fitted with various suitable connectors and terminations, including selectively closable sealing plugs at 1032.
  • FIG. 24 and 24A Another modified embodiment composite sheet panel system 1042 is shown in Figs. 24 and 24A and includes a spacer matrix 1044 comprising multiple, individual spacers 1046 with generally flat, rectangular configurations extending between and providing a predetermined spacing between sheets 1048, thus defining a central space 1050.
  • the spacers 1046 can be arranged to direct, restrict and otherwise control fluid flow under various conditions of pressure and flow rate. For example, by providing a sufficient number of spacers 1046 with sufficient rigidity, the sheets 1048 can be separated under negative pressure, thereby avoiding a flap-valve closure effect resulting from the application of negative pressure.
  • Another modified embodiment composite sheet panel system 1052 is shown in Figs.
  • a spacer matrix 1054 generally comprising multiple cylindrical spacers or tubules 1056 with opposite ends 1058 open at respective sheets 1060 whereby tubule passages 1062 provide additional surface area, which is exposed to fluid from both sides of the panel system 1052.
  • This embodiment provides a relatively large exposed surface area, which facilitates pressure and fluid exchange between the system 1052 and the patient.
  • the tubules 1056 can comprise similar materials to the sheets 1060, e.g. perforated or semi-permeable, or they can comprise different materials chosen for appropriate permeability and other characteristics.
  • Fig. 26 shows the sheet panel system 1052 folded double and inserted into a wound for drawing the separated tissue portions together and for controlling fluid flow and pressure application in order to facilitate wound closure.
  • the ports 1032 can apply positive or negative pressure and can inject or extract fluid.
  • the operation of the closure system 1052 can be sequenced as appropriate, with predetermined durations for different phases of the wound treatment procedure. For example, positive and negative pressures can be alternately applied. Fluids, such as antibiotics, analgesics, anesthetics and growth factors can be applied in predetermined dosage levels for predetermined durations.
  • FIG. 27 Another modified embodiment composite sheet panel system 1072 is shown in Fig. 27 and is similar to the panel system 1052, except that cylindrical spacers or ⁇ tubules 1074 thereof are closed at their respective ends by sheets 1076.
  • Figs. 28, 28A and 28B show yet another modified embodiment composite sheet panel system 1082, which is similar to the system 1072 except that the cylindrical spacers 1074 are replaced with spheres 1084.
  • Figs. 29 and 29A show another alternative embodiment construction of a composite sheet panel system 1092 with a pair of sheets 1094, each of which includes multiple hemispherical protrusions 1096, which are aligned with the sheets 1094 placed together to form multiple pockets 1097, which can be accessed by suitable manifolds and ports. As shown in Fig. 29A, the protrusions can be perforated with passages 1098 for communicating fluid with the pockets 1097. Fig.
  • FIG. 30 shows another alternative embodiment composite sheet panel system 1102 with a sheet 1104, which can be similar to the sheets 1094, covered by a membrane 1106.
  • Fig. 31 shows the composite sheet panel system 1092 in a wound with a transducer component 1006 placed in communication with the composite sheet panel system 1092 and located adjacent the skin surface.
  • a membrane cover 1010 is placed over the transducer component 1006 and can be attached to a pressure source via a connector 1014 as described above.
  • Another application of the composite sheet panel system 1092 is shown in Fig. 32 and includes a transducer component 1006 placed in the wound and partially surrounded by the composite sheet panel system 1092, with a cover 1010 placed thereover.
  • FIG. 33 and 33A show a composite sheet panel system 1112 comprising another alternative embodiment of the invention with multiple, spherical pockets 1114 interconnected by a matrix of tubes 1116 for fluidic communication with external sources.
  • Figs. 34 and 34A show another modified embodiment composite sheet panel system 1122 with disk-shaped pockets 1124 and passages 1126 positioned on both sides of a pocket matrix 1128 including interconnecting tubes 1130. Sheets 1132 are placed on both sides of the system 1122 and manifolds 1134 are located along respective edges in communication with the tubes 1130.
  • Figs. 35-36 show another alternative embodiment composite sheet panel system 1142 with an inner transducer component comprising a sheet 1144 with spherical protrusions 1146 defining outwardly-open pockets 1148.
  • An intermediate transducer component 1150 is placed over the first transducer component 1144 and an outer transducer component 1152 with spherical elements 1153 is placed over the intermediate transducer component 1150.
  • a cover 1110 is placed over the transducer components 1144, 1150, 1152 and can be connected to an external pressure source by a connector 1154 via tubing 1156. As shown in Fig.
  • Fig. 37 shows a composite sheet panel system 1162 comprising a modified embodiment of the system 1142 with an opening 1164 formed in the outer transducer component 1152 for receiving a connector 1114 in contact with the lateral transfer sheet intermediate transducer component 1150. Juxtaposition of these shapes creates a controlled capillary space, which allows faster, more distal movement of fluid.
  • Fig. 38 shows another alternative embodiment wound treatment system 1172 with an inner transducer component comprising a layer of beads 1174 located generally under an outer transducer component 1176.
  • the beads 1174 can comprise living cells, various pharmacological agents or a matrix for facilitating fluid and pressure transfer.
  • Figs 39 and 40 show another alternative embodiment wound treatment system 1182 with first and second sheets 1184 attached at disk-shaped connections 1186, which are similar to the spot welds 1026 described above, except with perforations 1188.
  • perforations 1188 In lieu of the multiple perforations 1188 shown, various sizes of single openings could be provided or the disk-shaped connections 1186 could be porous material.
  • Manifolds 1190 can be placed along the longitudinal and/or transverse edges of the sheets 1184 and connected to an external fluid and pressure sources as described above.
  • the system 1182 can be placed between a transducer component 1006 and tissue 1005 whereby fluidic communication can occur through the perforations 1188.
  • the sheets form pockets interconnected to form a fluid passage interstitial space 1192, which can be maintained with positive pressure, for example, to provide a smooth, uniform surface for clinical applications such as reepithelialization.

Abstract

A wound therapy and tissue management system utilizes fluid differentiation. Fluid is differentiated by establishing a gradient within the system. A gradient can be established with matter or energy. Patient interfaces for establishing, maintaining and varying one or more gradients include transfer elements with first and second zones having different flow coefficients. The transfer elements exchange fluid with a patient, generally through a wound site, and with external components of the system. Osmotic solution gradients are controlled by a methodology involving the present invention for extracting solutions, which can include toxins, from patients and for introducing fluids and sumping air to wound sites.

Description

Gradient Wound Treatment System and Method
Technical Field The present invention relates generally to medical care, and in particular to wound therapy and tissue management systems and methodologies with fluid differentiation.
Background Art Heretofore, many wound therapy and tissue management devices and protocols have tended to focus on the addition or control of individual mechanical forces and their respective effects on wound healing. For example, the use of suction to- secure skin graft dressings in place is disclosed in Johnson, F. E., An Improved Technique for Skin Graft Placement Using a
Suction Drain/ Surgery, Gynecology and Obstetrics 1984; 159 (6) : 584-5. Other prior art devices have focused on the application of compressive (i.e. positive or greater-than-atmospheric) pressure to a wound site, the application of heat and the delivery of pharmacologic agents.
Standard methods in the current practice of wound care require changing the dressing in order to topically add pharmacological agents, which require interval reapplication. Reapplications of pharmacological agents can be minimized or eliminated by using slow-release delivery systems. However, such systems must generally be changed in their entireties in order to change the agents or dosages.
Another wound treatment protocol option involves dosing the entire patient. Agents are thereby delivered systemically, i.e. from within the patient, in order to arrive at the wound site, as opposed to other protocols which deliver respective agents externally or topically. However, systemic medications are generally. administered in relatively high doses in order to provide sufficient concentrations in affected areas and treatment sites. Non-affected tissues and organs remote from the treatment sites thus tend to receive concentrations of medications from which they may not benefit .
Fluid management significantly affects many aspects of health care and is involved in many medical procedures . For example, wound care typically involves absorbing and/or draining wound exudates, blood, serum and other body fluids from the patient. Surgical procedures often create wounds requiring tissue management and fluid drainage. For example, skin grafts have exudates and bleeding that require management at both the donor and graft sites. However, current tissue management and fluid drainage procedures are often ineffective in maintaining optimum moisture content for promoting wound healing. Excessive drying, on the one hand, can lead to desiccation, eschar formation and slowing of cell migration. Excessive moisture, on the other hand, can lead to maceration, bacterial overgrowth, tissue breakdown and necrosis. Various types of porous, absorbent dressing materials have been used for dressing wounds to accumulate body fluids . The dressing materials facilitate drainage and also the collection and disposal of fluids. A disadvantage with many conventional dressings is that they require changing in order to reduce the risk of infection and to maintain effectiveness. However, dressing changes' can add significantly to treatment costs and are associated with patient discomfort and medical risks such as infection and damage to reepithelialized tissues. Accordingly, vacuum sources have been employed to drain wounds. For example, Zamierowski U.S. Patents No. 4,969,880; No. 5,100,396; No. 5,261,893; No. 5,527,293 and No. 6,071,267 pertain to wound dressings, fluid connections, fastening systems and medical procedures utilizing same in connection with vacuum-assisted wound drainage, and are incorporated herein by reference.
A wound drainage device using a hand-operated suction bulb is shown in the George et al. U.S. Patent No. 4,392,858. Motorized suction pumps can be employed to provide consistent, sub-atmospheric vacuum pressure for maintaining an effective drainage flow. The Richmond et al. U.S. Patents No. 4,655,754 and No. 4,826,494 disclose vacuum wound drainage systems which can be connected to motorized vacuum pumps. Another important objective in designing an effective wound drainage system is to provide an effective interface with the patient. Ideally, the patient interface should accommodate various types of wounds in different stages of recovery for as . broad a range of applications as possible. As noted above, optimum wound healing generally involves maintaining a sufficient moisture level to avoid desiccation without causing the wound to macerate from excessive moisture. Sufficient moisture levels are required for epithelial cell migration, but excessive moisture can inhibit drying and maturation of the epithelial layer. Pressures should be sufficient for effective drainage without creating excessive negative forces, which could cause pressure necrosis or separate freshly-applied skin grafts.
Wound treatment procedures can also include infusing wound sites with liquids to flush contaminants, counter infection, promote healing growth and anesthetize the wound. Prior art fluid delivery systems include a device for treating tissues disclosed in the Svedman U.S. Patent No. 4,382,441; a product and process for establishing a sterile area of skin disclosed in the Gross U.S. Patent No. 3,367,332; and the transdermal infusion device disclosed in the Westin U.S. Patent No.
4,605,399. Equipment has also been available which flushes and collects contaminants from wounds . Heretofore, there has not been available a system or methodology that allowed the manipulation of multiple mechanical forces affecting wound surfaces. Moreover, there has not previously been available a system or methodology that manipulated the gradients of gases, solids, liquids and medications in such a way as to provide the medical practitioner with various options for delivering various agents either systemically from the patient side or topically from the external side of a wound. Further, there has not been available a. system or methodology which affected the removal of toxins and undesirable byproducts by an external egress with the advantages and features of the present invention. Such advantages include minimizing or eliminating dressing changes whereby patient discomfort and infection risks are correspondingly reduced. Effective control of fixation, temperature, pressure (and its associated gradients for vital gases such as oxygen) , osmotic, and oncotic forces, electrical and electromagnetic fields and forces and the addition and/or removal of various nutrients and pharmacological agents have not been achievable with the previous systems and methodologies. Still' further, there has not been available a wound treatment system and methodology utilizing a transfer element for the manipulation of gas and liquid pathways under the control of pre-programmed, coordinated influx and efflux cycles. Such cycles are designed to maintain the desired integrity and stability of the system while still allowing variations in multiple forces, flows and concentrations within tolerated ranges. The previous wound treatments also tended to lack the dynamic and interactive features of the present invention whereby various gradients can be .adjusted in response to patient wound site conditions. Such gradient adjustments can be accomplished with the present invention through the use of biofeedback loops and patient-responsive sensors.
Osmotic and concentration gradients provide an important mechanism for transferring various elements within the scope of the present invention. Such gradients occur naturally in living organisms and involve the movement of solutes from solutions with greater concentrations to solutions with lesser concentrations through semi-permeable membranes. Osmosis is the tendency of solids to pass through semi-permeable membranes into solutions of higher concentrations in order to achieve osmotic equilibrium. Diffusion occurs from an area of higher concentration or partial pressure to an area of lower concentration even without membrane separation. Examples include the diffusion transfer of oxygen from alveoli to capillaries within the lung and the osmotic transfer of toxins and waste within the kidneys from capillaries to tubules and on to the bladder. The systems and methods of the present invention utilize and control osmotic and diffusion gradients to advantage in treating wounds, particularly in connection with the removal of toxins and solution from wound sites by controlling fluids. The control of fluids originates both internally and externally. For example, wound exudates originate internally. External control fluids include sumped air, irrigation, etc.
Previous wound treatment systems and methodologies did not provide medical practitioners with the range of options available with the present invention for treating various patient circumstances and conditions.
Disclosure of Invention
In the practice of the present invention, a wound therapy and tissue management system is provided, which includes a collector assembly for attachment to a patient, a transfer assembly connected to the collector assembly and a gradient (e.g., negative pressure/vacuum, positive pressure, temperature, oxygen, etc.) source connected by tubing to the transfer assembly. The system is adaptable for use with various dressing assemblies, including multiple layers and components comprising hydrophobia and hydrophilic foam and sponge materials, semi-permeable and impermeable membranes applied as drapes, transfer system conduits and buffers, and tubular connections to pumps. Alternative embodiments of -the system utilize osmotic gradients for controlling transfers and provide various optional configurations with internal and external inputs, installation ports and other components. In the practice of the method of the present invention, a fluid differentiation wound therapy and tissue management method is disclosed, which includes steps of shaping and applying a first sponge comprising a first sponge material to a wound area, applying a first drape, shaping and applying a second sponge comprising a second sponge material on top of the first drape and the first sponge, forming a fluid conduit and connecting same to the second sponge and to a buffer for ultimate connection to a vacuum pump. The conduit and the buffer are also draped. Osmotic wound therapy and tissue management methodologies are also disclosed in connection with the present invention. The transfer of fluids and substances such as toxins can be controlled through the application of such methodologies. In the practice of other aspects of the present invention, osmotic transducers are provided for treating wounds by manipulating the gaseous, liquid and solid components in such a way as to create pressure gradients in fluid elements that produce useful fluid flow.
Brief Description of Drawings
Fig. 1 is a block diagram of a vacuum-fixed wound therapy system embodying the present invention.
Fig.2 is a perspective view of a composite dressing assembly.
Fig.3 is a vertical cross-sectional view of the dressing assembly taken generally along line 3-3 in Fig.2.
Fig..4 is an enlarged, fragmentary, cross-sectional view of a composite dressing- comprising a first modified embodiment of the present invention.
Fig.5 is a perspective view of a composite dressing comprising a second modified embodiment of the present invention.
Fig. 5a is a perspective view of a variation of the embodiment shown in Fig. 5.
Fig. 6 is a perspective view of a transfer assembly for a composite dressing comprising a third modified embodiment of the present invention.
Fig. 7 is a cross-sectional view of a third modified embodiment composite dressing.
Fig. 8 is a perspective view of the third modified embodiment composite dressing.
Fig. 9 is a perspective view of a composite dressing comprising a fourth modified embodiment of the present invention.
Fig. 10 is a flow diagram of a vacuum-fixed wound, therapy method embodying the present invention.
Fig. 11 is an exploded view of a wound treatment system with vacuum, heat and fluid assistance.
Fig. 12 is an exploded view of another wound treatment system with vacuum, heat and fluid assistance. Fig. 13 is an exploded view of yet another wound treatment system, with vacuum, heat and fluid assistance.
Figs.l4a-d comprise graphs showing the temperature- elevating performance of the wound treatment systems shown in Figs 11-13.
Fig. 15 is a block diagram of a wound therapy and tissue management system comprising an eighth alternative embodiment of the present invention.
Fig. 16 is a schematic diagram of the eighth alternative embodiment wound therapy and tissue management system.
Fig. 17 is a flowchart of a wound and therapy- and tissue management methodology embodying the present invention. Fig. 18 is a block diagram of a wound therapy and tissue management system comprising a ninth alternative by the present invention.
Fig. 19 is a diagram showing various phases in a hyperosmolar or air-sump system embodying the present invention. Fig. 20 is a diagram showing various phases in an osmolar or isotonic flush or rinse system embodying the present invention.
Fig. 21 is a diagram showing a hypo-osmolar or heavy drape system embodying the present invention. Fig. 22. is a diagram showing a generic model of a gradient wound treatment system.
Fig. 23 is a perspective view of an alternative embodiment composite sheet panel system.
Fig. 23A is a cross-sectional view thereof, taken generally along line 23A-23A in Fig. 23.
Fig. 24 is a perspective view of another alternative embodiment composite sheet panel system.
Fig. 24A is a cross-sectional view thereof, taken generally along line 24A-24A in Fig. 24. Fig. 25 is a perspective view of another alternative embodiment composite sheet panel system.
Fig. 26 is a perspective view thereof, shown installed in a wound for closing same.
Fig. 27 is a perspective view of another alternative embodiment composite sheet panel system.
Fig. 28 is a perspective view of another alternative embodiment composite sheet panel system.
Fig. 28A is a cross-sectional view thereof, taken generally along line 28A in Fig. 28.
Fig. 28B is another cross-sectional view thereof, taken generally along line 28B in Fig. 28. Fig. 29 is a cross-sectional view of another alternative embodiment composite sheet panel system.
Fig. 29A is an enlarged, cross-sectional view thereof, taken generally within circle 29A in Fig. 29.
Fig. 30 is a cross-sectional view of another alternative embodiment composite sheet panel system.
Fig. 31 is a cross-sectional view thereof, shown in a wound for closing same.
Fig. 32 is another cross-sectional view thereof, shown in another wound for closing same Fig. 33 is a plan view of another alternative embodiment composite sheet panel system.
Fig. 33A is a cross-sectional view thereof.
Fig. 34 is a plan view of another alternative embodiment composite sheet panel system. Fig. 34A is a cross-sectional view thereof.
Fig. 35 is a cross-sectional view of another alternative embodiment composite sheet panel system.
Fig 36 is another cross-sectional view thereof, shown in a compressed, compacted configuration. Fig. 37 is a cross-sectional view of another alternative embodiment composite sheet panel system.
Fig. 38 is a cross-sectional view of another alternative embodiment gradient wound treatment system.
Fig. 39 is a perspective view of another alternative embodiment composite sheet panel system.
Fig. 40 is a cross-sectional view thereof, taken generally along line 40-40 in Fig. 39.
Best Mode for Carrying Out the Invention
I. Introduction and Environment.
As required, detailed embodiments of the present invention are disclosed herein; however, it is to be understood that the disclosed embodiments are merely exemplary of the invention, which may be embodied in various forms. Therefore, specific structural and functional details disclosed herein are not to be interpreted as limiting, but merely as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present invention in virtually any appropriately detailed structure.
II. Vacuum-fixed Wound Therapy Dressing 3. Referring to the drawings in more detail, the reference numeral 2 generally designates a vacuum-fixed wound therapy system for application to a wound 4 on or in a patient 5. The system 2 includes an improved dressing 3. Other components of the system 2 are described in my U.S. Patent No. 6,071,267, which is incorporated herein by reference .
The dressing 3 generally includes a collector assembly 6 and a transfer assembly 8 connected to a vacuum source 10. The collector assembly 6 includes a first sponge 12 comprising a hydrophilic material, such as polyvinyl alcohol (PVA) . The first sponge 12 is cut to generally conform to the size of the wound 4. A first sponge drape 14 is placed over the first sponge 12 and an opening 16 is formed in the drape 14 and is preferably sized smaller than the first sponge 12. The drape 14 encloses acompression chamber 15 containing the first sponge 12. A dry skin, moisture-control zone 17 is formed around the first sponge 12 due to air circulation within the compression chamber 15 and promotes healing.
A second sponge 18, preferably comprising a hydrophobic polyurethane ether (PUE) material is sized larger than the first sponge 12, whereby a second sponge overhang 20 extends beyond the perimeter of the first sponge 12. A second sponge drape 22 is placed over the second sponge 18 and includes an opening 24 located along an outer edge 26 of the second sponge 18 for directing the outflow of fluid effluent from the collector assembly 6.
The transfer assembly 8 includes a conduit 28, which can comprise the same hydrophobic material as the second sponge 18. The conduit 28 includes an inlet end 30 which is offset in order to overlie the second sponge drape opening 24 along the second sponge outer edge 26. A conduit outlet end 32 mounts a buffer 34, which also preferably comprises the hydrophobic foam and projects outwardly from the conduit 28 and receives a suction tube 36 which is also connected to the vacuum source (e.g., pump) 10. A conduit drape 38 overlies the conduit 28 and includes an opening 40, which receives the buffer 34. A buffer drape 42 includes a first panel 42a and a second panel 42b, which are secured together over the buffer 34 and the suction tube 36 to enclose same. The buffer drape first and second panels 42a, b are mounted on the conduit drape 38 around the opening 40 therein.
In operation, the hydrophilic first sponge 12 tends to collapse under negative pressure. Therefore, the size of the first sponge 12 is limited and it is preferably mounted inproximity to an edge 26 of the second sponge 18. The second sponge 18 cooperates with the transfer assembly to distribute the negative pressure throughout the hydrophobic second sponge 18 and in turn throughout the first sponge 12. The PVA material comprising the first sponge 12 permits it to compress under a negative pressure gradient. Moreover, because the fluid travel distance in the first sponge 12 tends to be relatively short due to its composition, the overlying second sponge 18 tends to distribute the negative pressure gradient relatively evenly across substantially the entire area of the first sponge 12. The PUE composition of the second sponge 18 provides a retriculated latticework or weave which resists compression and includes relatively open passages to facilitate fluid flow. Although such open-lattice construction has operational advantages, the passages formed thereby in the second sponge 18 tend to receive "spicule" penetrations from the wound, which is undesirable in many applications. Therefore, the collector assembly 6 is constructed by first forming the first sponge 12 to generally conform to the wound 4, whereafter the second sponge 18 is formed to provide the overhang 20. The first sponge 12 is covered with the first sponge drape 14, the opening 16 of which is normally sized smaller than the overall area of the first sponge 12.
The functional advantages of the collector assembly 6 construction include optimizing compression and fixation and edema control at the wound edge while maximizing the air-induced drying of the intact skin in the dry skin zone 17. Moreover, collector assemblies and transfer assemblies can be mixed and configured in a wide variety of arrangements to accommodate various patient conditions. For example, multiple transfer assemblies 8 can be connected to a single collector assembly 6 and vice versa.
III. First Modified Embodiment Fluid Differentiating Wound Dressing 53
A wound dressing 53 comprising a first modified embodiment of the present invention is shown in Fig.4 and includes a liner 54 between the wound 4 and a first sponge 56, which can comprise a hydrophilic or hydrophobic material. The liner 54 passes fluid, but partially isolates and shields the wound tissue from the first sponge 56 to prevent the formation of spicules penetrating the open-passage first sponge 56. The liner 54 thus permits the first sponge 56 to comprise hydrophobic (e.g., PUE) material, even when spicule penetration is not desired.
IV. Second Modified Embodiment Fluid Differentiating Wound Dressing 102 A wound dressing comprising a second modified embodiment of the present invention is shown in Fig. 5 and generally comprises a collector assembly 106 and a transfer assembly 108. The collector assembly 106 can be similar to the collector assembly 6 with a suitable composite construction. The transfer assembly 108 comprises an elbow connector 110 placed on top of a second sponge drape 112 covering the second sponge 114. The elbow connector 110 mounts the distal end 116 of a suction tube 118, which is also connected to a vacuum source 10. A first sponge drape 120 is placed over a first, hydrophilic sponge 122 and includes a central opening 123 communicating with the second sponge 114.
Fig. 5a shows an interface device 102a comprising a variation of the construction of the wound dressing 102. The device 102a utilizes a flexible, bellows-type tubing section 1 10a in place of the elbow connector 110 described above. A needle-free, leur lock hub 124a is mounted on the end of the tubing section 1 10a and functions as an injection port. It will be appreciated that the sponge 122 can be omitted from the dressing 102a whereby same can be used as a fluid inlet or outlet in various applications and on many different configurations of dressings.
V. Third Modified Embodiment Fluid Differentiating Wound Dressing 202
A fluid differentiating wound dressing 202 comprising a third modified embodiment of the present invention is shown in Figs.6-8 and generally comprises a transfer assembly 204 (Fig.6) adapted for mounting on a collector assembly 206 as shown in Fig.7.
The transfer assembly 204 comprises a sponge material buffer 208 which can comprise, for example, polyurethane ether (PUE) . The buffer 208 is encased in first and second drape panels 210, 212 with wings 210a, 212a respectively extending in opposite directions from the buffer 208. The wings 210a, 212a have an adhesive layer 214, which is covered by a removable backing sheet 216 prior to installation. Tab strips 218 are provided at the ends of the drape wings 210a, 212a. The tab strips 218 are attached by perforated lines 220 for easy removal upon installation. The suction tube 36 is embedded in the buffer 8 and extends outwardly from the transfer assembly 204 from between the first and second drape panels 210, 212. An optional leur-lock hub to 13 is mounted on the end of the tube 36 for injection port applications.
The transfer assembly 204 is adapted for mounting on a collector assembly 206 (Fig.7), which is similar to the collector assembly 6 described above. An opening 224 is formed in a second drape 222 which overlies a second sponge 218. With the backing sheet 216 peeled away, the adhesive layer 214 on the drape panel wings 210a, 212a secures the transfer assembly 204 in place whereby the buffer 208 is in communication with the second sponge 218 through the opening 224. An optional first sponge 212 can be placed on the wound 4 and covered with drape 214 with an opening 216 formed therein. The dressing 202 can also be utilized with a single sponge for the collector assembly 206.
Fig. 8 shows an application of the dressing 202 wherein the transfer assembly 204 is mounted over a medial or interior portion 218a of the second sponge 218. A first end 208a of the buffer 208 can be folded substantially flat on top of the second drape which overlies the second sponge 18. A second end 208b of the buffer 208 extends outwardly from the collector assembly 206. The buffer 208 can flex in response to pulling forces tugging on the suction tube 236. The dressing 202 as shown in Fig. 8 is wrapped with drape strips 222, which are adapted for encircling an extremity of a patient. Thus, the buffer first end 208a is secured by a drape strip 222 as shown. The drape strips 222 can be utilized for applying a compressive force to the dressing 202. In operation, evacuating the dressing 202 causes portions of it to shrink, compress and collapse under the pressure gradient, thus providing a visual indication of its performance .
VI. Fourth Modified Embodiment Fluid Differentiating Wound Dressing 302
Fig. 9 shows a fluid differentiating wound dressing 302 comprising a fourth modified embodiment of the present invention. The dressing 302 includes a collector assembly 304 and a transfer assembly 306 . The collector assembly 304 includes first and second sponges 308, 310. The first sponge 308 is mounted on the wound and can comprise, for example, a hydrophilic foam material as described above. The second sponge 310 can be mounted directly on the first sponge 308 (optionally separated by a drape) and can receive a tube 312 connected to a vacuum source. The second sponge 310 can include an overhang 313 extending beyond the first sponge 308 for providing a compression chamber 315 as described above. A drape 314 is placed over the collector assembly 304 and the tube 312. The drape 314 is folded over the tube 312 whereby same is spaced outwardly from the skin, thus providing an effective, fluid-tight seal around the tube 312.
VII. Vacuum-Fixed Wound Therapy Method
Fig. 10 shows a wound therapy method embodying the present invention. The method can be performed with one or more of the systems discussed above, including the vacuum-fixed dressings 3, 53, 102, 202 and 302. The method can also be performed with a wide variety of variations on the systems and dressings disclosed above .
VIII. Fifth Modified Embodiment Wound Therapy And Tissue Management System 402
Fig. 11 shows a wound therapy and tissue management system 402 comprising a fifth modified embodiment of the present invention. The system 402 includes a dressing 404 placed on a wound 406. Any of the dressing systems discussed above can be utilized. The enclosure 414 is placed over the wound site 406 and includes an opening 416 extending therethrough and adapted for receiving a warming card 418 in covering relation thereover. The warming card 418 is operationally connected to1 a temperature control unit 420. A vacuum assisted closure unit 408 is fluidically connected to the enclosure 414 by a suitable suction tube and in turn is connected to a power source 410.
In operation, the warming card 418 is heated and raises the temperature within the enclosure 414 to promote healing. The vacuum assisted closure 408 functions as described above to remove effluent and to promote healing in cooperation with the warming card 418. Warming cards and other components for use in connection with this embodiment of the invention are available from Augustine Medical Products, Inc.
IX. Sixth Modified Embodiment Wound Therapy and Tissue Management System 502 Fig. 12 shows a wound therapy and tissue management system 502 comprising a sixth modified embodiment of the present invention. The system 502 is similar to the system 402 described above. A composite dressing 504 is comprised of first and second layers 506, 508. A fluid source 518 communicates with a temperature control and pump unit 514 and provides influx to the system 502.
X. Seventh Modified Embodiment Wound Therapy and Tissue Management System 602. Fig. 13 shows a wound therapy and tissue management system 602 comprising a seventh modified embodiment of the present invention. The system 602 is similar to the systems 402 and 502 described above. A transfer element 604 is covered by a drape 620, which mounts a film 616 adapted for receiving a warming card 618.
XI. Test Data
Figs. 14a-14d shows the results of tests performed with the dressing systems and methodologies discussed above and variations thereon. Fig. 14a shows system performance (time and temperature) with a dry PUE hydrophobic sponge material. Fig. 14b shows system performance with a wet PVA hydrophilic sponge material. Fig. 14c shows performance with an irrigated PUE hydrophobic sponge material with a warm-up plate (heating card) and a cover. Fig. 14d shows system performance with both PUE hydrophobic sponge material and PVA hydrophilic sponge material.
XII. Wound Therapy and Tissue Management System 702
Figs. 15 and 16 show a wound therapy and tissue management system 702 comprising an eighth modified embodiment of the present invention. The system 702 is shown schematically in Fig. 15 and consists of inputs 704, the patient 706, outputs 708 and a feedback loop 710. The inputs 704 can comprise virtually any matter or energy deemed appropriate for the treatment protocol by the health-care practitioner. For example, various irrigation fluids, growth factors, antibiotics, anesthetics, etc. can be input to the patient 706. Still further, the inputs can comprise various forces and energy forms whereby a matter/energy gradient is established with respect to the patient 706.
For example, negative pressure from a suitable vacuum source (such as a VAC unit available from Kinetic Concepts, Inc. of San Antonio, Texas) can be an input for creating a negative pressure gradient across the system. Likewise, positive pressure from a suitable fluid pump can be input to establish a positive pressure gradient across the system. Other forces can provide electromagnetic, electrical, mechanical and thermal gradients. The system 702 monitors performance of the patient 706 and controls the inputs 704 interactively in response thereto. Parameters which could be monitored for feedback purposes included moisture levels, temperature, bacteria levels, fluid pressure, etc. The presence or absence of particular elements and compounds can also be sensed, monitored and acted upon. For example, is widely known that oxygen is an important factor in wound healing. Studies have shown that reepithelializationand collagen production are best achieved by varying the oxygen supply. Thus, the oxygen level within the enclosed, wound site environment can be monitored and the oxygen levels therein either increased or decreased as necessary to promote healing. Other controllable parameters include the pH factor and the moisture concentration of the wound environment. Various suitable monitoring means can be employed, including electronic sensors, visual indicators, color-change substances, etc.
The output from the patient can consist of fluid, such as effluent from the wound site, irrigation fluid removed in the process of flushing the wound site, and other matter and energy. An important function of the system is the removal of toxins and bacteria, which can be flushed from the wound site in a liquid or fluid solution. Fig. 16 is a block diagram of the system 702, showing the components thereof in greater detail. A programmable controller 712 can be preprogrammed to operate the system according to predetermined protocols. The controller 712 is connected to and controls the operation of the input source 714 and the gradient source 716. The input source 714 can comprise any suitable matter or energy for input to the system 702, including various fluids, medications, thermal energy, mechanical forces, temperature, etc., as discussed above. The gradient source is likewise unlimited. For example, pressure gradients (both positive and negative) are particularly suitable for controlling the operation of the system 702 for draining wounds. Other types of gradients include temperature, osmotic, oncotic, pH, oxygen demand, bacteria concentrations, etc., as discussed above. A gradient source 716 can comprise any suitable device for establishing a gradient. For example, a vacuum source can be utilized for creating a negative pressure gradient. A pump can be utilized for creating a positive pressure gradient. A drape 718 is placed in covering relation over a transfer element 720. The drape 718 can comprise any of the film materials discussed above and can be permeable, semi-permeable or impervious. The transfer element 720 includes a first zone 720a with a first set of fluid flow characteristics and a second zone 720b with a second set of fluid flow characteristics. Such fluid flow characteristics can be a function of material, thickness, porosity, permeability, and sponge material attraction to proteins, fat cells and other substances. The zones 720a, b can be formed by providing layers of the material, by providing varying thicknesses, by interspersing a first material within a second material in predetermined configurations, etc.. Still further, the first and • second zones can be formed by subjecting the transfer element 720 to an electromagnetic field.
The first and second zones 720a,b can also be formed by varying the density of the transfer element 720, as indicated by the dashed line 732 (Fig. 16) . Line 732 represents compressed material (e.g., foam) along one edge and expanded material in the second zone 720b. Such density gradients can be achieved by compressing the material or by heat-setting same in a manufacturing process. Transfer element 720 edges can also be compressed when the dressing is applied to achieve a desired density gradient. Material thickness can also be utilized to provide a flow coefficient gradient. In this case line 732 could represent a tapering of the transfer element 720 across the first and second zones 720a, 720b. A marbling effect with a material concentration gradient is shown at 733, with greater concentration along an edge and decreasing concentration towards interior portions of the transfer element 720, or vice-versa. Constructing the first and second zones 720a, 720b of different materials with different respective flow coefficients could also achieve a desired flow gradient.
Medications and other substances can be applied to the transfer element materials to alter the flow characteristics thereof. Systemic agents 731 can be administered to the patient 726.
Fluid 722 can be introduced into the wound site 724 from the inputs 714 and its flow pathways can be controlled by the gradient source 716. For example, sponge materials with different flow characteristics can be configured to direct fluid (either gas or liquid) in predetermined flow patterns through the transfer element 720. Effluent 728 from the patient 726. is withdrawn from the wound site 724 and evacuated to a collection receptacle 730.
XIII. Wound Therapy and Tissue Management Methodology
Fig. 17 shows a flowchart for a wound therapy and tissue management methodology embodying the president mentioned. From Start 804, the method proceeds to Diagnose Patient Condition 806. Based on the diagnosis, a treatment protocols selected. The protocol includes an identification of a gradients to be controlled by the methodology. For example, protocols involving vacuum-assisted wound drainage will generally include a negative pressure gradient. Additional possible gradients are discussed above. It will be appreciated that virtually unlimited combinations of gradients can be formed in the system 702.
Moreover, the timing of the gradient control can be varied as needed to achieve desired treatment results. For example, . collagen production and reepithelialization can be promoted by hyperbaric oxygen treatment procedures, such as alternating elevated and reduced oxygen concentrations . Suction/compressive pressures can also be alternated to stimulate tissue growth. Gradient sources are provided at 810 and can comprise vacuum/suction, fluids, medications, oxygen and various other matter and energy. Gradients can also be formed utilizing energy sources, such as thermal, mechanical force, etc. First and second transfer characteristics are selected at 812, 814 respectively. A transfer element (s) is provided at 816 and includes the transfer characteristics selected at 812, 814. The patient is prepared at 818. Patient preparations can include any suitable medical procedures, such as debriding the wound, etc.
The transfer element is applied at 820 and draped at 822. The transfer element is connected to a gradient source at 824 and the gradient is applied at 826. Fluid is transferred through the first transfer element zone at 828 and through the second transfer element zone at 830. It will be appreciated .that such transfer zones can be adapted for directing the fluid along certain pathways to achieve desired results, such as evacuation of exudates. The fluid is differentiated (e.g., liquids, gases or liquids and gases are separated) at 832.
The operating parameters are monitored at 834 and the gradient source (s) are adjusted accordingly add 836. Thereafter a "Continue?" decision box 838 is reached. If affirmative, the method returns to Apply Gradient 826 and operation continues with the adjusted gradient parameters. A negative decision at 838 leads to a termination of the procedure (i.e., "End") at 840.
XIV. Osmotic Gradient Wound Therapy and Tissue Management System 902 and Methodology
Figs. 18-21 show a wound therapy and tissue management system 902 and methodology utilizing a controlled osmotic gradient. A patient 904 includes capillaries 906 which provide fluid, such as serum and blood, to a wound 908. Such fluid passes to the transfer element 910. An air sump control 914 communicates with the transfer element 910 through an air sump conduit 912. A discharge control 918 communicates with the transfer element 910 through a discharge conduit 916. The controls 914, 918 are interactively controlled by a controller 922, which is adapted to receive control input signals. Such input signals can comprise, for example, preprogrammed inputs, feedback signals (Fig. 15) , etc.. The input signals can originate at sensors associated with the system 902 and with the patient 904. Such inputs can effectively control the osmotic gradient to achieve desired fluid, solvent and solute (e.g., toxin) transfers. For example, the primary external substance input can comprise relatively dry ambient air. Air movement through the system 902 tends to collect moisture for discharge as water vapor . The system 902 is covered by a drape 920, which can comprise various semi-permeable and impervious materials as required by fluid flow considerations and various applications. For example, an impervious drape 920 tends to block air from the system 902 and permit entry of same only through the air sump control 914.
Fig. 19 shows a hyperosmolar or air-sump system. Phase 1 represents a steady-state or increasing-toxin A condition and a concomitant increasing movement of toxin A back into the patient. In phase 2 a hyperosmolar solution or air sump is introduced. This gradient draws fluid from the capillaries to replace the fluid moved out of the wound into the transfer element carrying toxin A with it and decreasing movement of toxin A into the patient. Alternatively or in addition, warmed irrigating fluid can be introduced into the transfer element in phase 2. The advantages of warming the transfer element and wound site in this manner include vasodilation, increase in cell motility and an increase in phagocytosis. For example, irrigating fluid warmed to approximately 40 degrees centigrade has been shown to remove the inhibitory effect of chronic wound fluid on cell culture motility and proliferation.
In phase 3, ongoing administration of this gradient continues these fluxes as water vapor is removed and dry air is sumped. In phase 4 is results in a new steady-state condition with lower levels of toxin A in the wound (and the patient) and increased fluid and toxin A in the transfer element that is continuously evacuated. [Fig. 20 shows an isosmotic or isotonic flush or rinse methodology.
In phase 1 there is a steady-state (or increasing toxin A level) condition with fluid (liquids) moving out from the wound to the transfer element being replaced by serum exudate from the capillary. Evaporative loss from the transfer element is kept to a minimum by application of a drape material.
In phase 2, an isomotic rinse is introduced, increasing the fluid content of the transfer element and decreasing the concentration of toxin A, enabling a diffusion of toxin A from the wound into the transfer element. In phase 3, as this fluid is withdrawn, it also removes toxin A, enabling a continued diffusion of toxin A put of the wound. In phase 4, the resulting condition is fluid equilibrium and decreased concentration of toxin A in the wound. As this situation reverts to phase 1, the flush or rinse is repeated at intervals.
Fig. 21 shows a hypo-osmolar or heavy drape system. In phase 1 steady-state conditions generally exist with some evaporative loss of fluid (water vapor) . In phase 2, small amounts of hypo-osmolar fluid are introduced, or a cover/drape is placed over the transfer element with a heavy drape completely blocking evaporative loss, thus adding "free water" to the system. This reverses the outward flow of fluid from the wound.
In phase 3 this increased fluid in the wound allows the total amount of toxin A to also accumulate in the wound. In phase 4 this increase of fluid and toxin A in the wound without any egress produces movement of fluid (edema) and toxins (cellulitis) back into the patient and into the lymphatics .
XV. Generic Model and Additional Modified Embodiments
Fig. 22 shows a generic, model of an osmotic transducer system 1002 for treating a wound 1004 by manipulating the gaseous, liquid and solid components in such a way as to create pressure gradients in fluid elements that produce useful fluid flow. The system 1002 is shown applied to an exposed tissue layer 1005. A pressure transducer component 1006 can comprise a porous hydrophobic material, such as polyurethane ether (PUE) foam, or a hydrophilic material, such as polyvinyl alcohol (PVA) foam. Alternatively, various other materials with suitable fluid mechanics and handling properties can be utilized, including naturally-occurring or man-made materials, or both.
The pressure transducing function of the component 1006 involves several different kinds of pressures from different sources, which are generally designated P in Fig. 22. For example, gas components can be changed or gas pressure relative to ambient air can be changed, producing gradients. Osmotic and/or oncotic liquid pressures can be involved in causing patient fluid to flow through the system 1002. Capillary pressure is a function of the spaces in the solids or materials comprising the transducer component 1006. Moreover, the tissue layer 1005 also functions as a transducer for pressure P. Externally-applied pressure P can originate at a negative pressure source, such as a vacuum puπφ, or at a positive pressure source, such as a fluid pump.
In its simplest form (e.g., the generic model shown in Fig. 22) the transducer system 1002 includes a base element 1008 generally comprising the transducer component 1006 partly surrounded by a cover 1010. The fluids acted on can be gaseous or liquid. Many applications will involve both. The base element 1008 communicates and interacts with its environment. Gradients are actively established by the containment and manipulation of the base element 1008.
Gradients can also be established passively with the base element in a static or ambient mode or condition.
The cover or membrane 1010 modulates fluid pressure or flow by its physical properties of rigidity and flexibility, which can resist movement associated with a pressure gradient across the two sides of the cover or membrane 1010 and, conversely, the ability to collapse or change shape as a result of this gradient. Changing fluid pressure and volume modulates osmotic, capillary and atmosphere pressures, thereby changing the shape of the cover 1010. For example, changing the size and/or shape of the cover 1010 can produce fluid gradients by changing solvent volume for osmotic pressure, tube radius for capillary pressure and fluid volume/container volume for atmospheric pressure. The porosity of the cover 1010 to fluids and solutes is another physical property, which affects fluid pressure and/or flow modulation by the cover 1010. For example, cover 1010 porosity can range from porous to semi-permeable to impervious. Semi-permeable covers 1010 are generally selectively capable of passing certain gaseous (vapor) phase elements and are impervious to certain liquid phase substances. Such selective permeability for various sizes of solutes, which can be a function of pore size, can be used for selectively creating fluid flow conduits for certain substances with the cover 1010.
The transducer component 1006 is located in a central or contained space 1012 generally defined by the cover 1010 and the tissue layer 1005, and can also be designed to manipulate fluid pressure and flow. Selective permeability for various sizes of solutes, which can be a function of pore size, can be used for selectively creating fluid flow conduits for certain substances with the transducer component 1006. The' space 1012 can contain fluid alone, with or without solutes, or fluid and an engineered solid (e.g. bioengineered cells, beads, etc.) . Fluid gradients for directing flow can be created, controlled and manipulated as a function of osmotic, capillary and atmospheric pressures.
Osmotic pressure control can be utilized with gas, liquid (with or without solutes) or both. By adjusting the concentrations of dissolved elements, a gradient can be established across the cover 1010 between the transducer component 1006 and the external environment. Capillary pressure control can involve transducer component 1006 configurations such as screens and three-dimensional meshwork providing channels and passages with predetermined sizes. A gradient can thereby be produced across the cover 1010, and can be engineered to modulate in response to the amount of fluid that is flowing. The transducer component 1006 can comprise, for example, an absorbable meshwork, which swells with liquid absorption whereby the spaces and passages change with exposure to liquid and cause corresponding changes in the capillary pressure gradients. The transducer component 1006 meshwork can be configured to hold more fluid at increased pressures (e.g., changing volume under osmotic pressure), thereby stretching the cover 1010, physically changing the conduit and passage sizes and modulating the pressure gradients and corresponding fluid flow.
Atmospheric pressure can remain constant through volume changes if the cover 1010 is sufficiently flexible -to accommodate such changes. Differential fluid pressures and other gradients can be created and manipulated by selective permeability and rigidity of the cover membrane 1010. Strong osmotic/oncotic pressures can be established across the cover 1010 in order to cause liquid to selectively cross into the transducer 1012. On the other hand, if the cover 1010 is less flexible or stretchable, pressures tend to change within the central space 1012. For example, dissolved oxygen may be present in the central space 1012 and may be forced out through the cover 1010 by an increase in pressure. A water removal/oxygen delivery system is thus created. Alternatively, a specific connector conduit portion can be established in the cover 1010 for allowing active (mechanical or otherwise) modulation of atmospheric pressure (both positive and negative) inside the transducer component 1006, with the resultant gradient and fluid flow changes that will result to the other phases and elements in the central space 1012.
The effects of the aforementioned pressures on the gradients and functions of the transducer system 1002 are interrelated, whereby changing one or more design variables can affect others and thereby provide a relatively high level of control.
The ambient atmosphere and environment external to the transducer system 1002 can also be part of the system and controlled in order to achieve various desired performance objectives. The external environment can be ambient, or it may be contained within a larger, secondary enclosure. Connectors or patches, such as the cover connector 1014, can be utilized for fluid and pressure communication to the system 1002 from external sources, e.g. through tubing 1016. For example, it may be desirable to control and manipulate certain atmospheric characteristics, such as oxygen content, humidity, etc. Such characteristics could remain relatively constant as elements are exchanged with the environment. Ambient liquids of various constitutions, concentrations and pressures can also comprise the ambient environment, and can be manipulated in order to achieve desired performance. Liquid volumes and concentrations can be sufficiently large for pressures and other characteristics to remain relatively constant contemporaneously with pressure gradient control and manipulation.
The tissue layer 1005 also has an interface relationship with the base element 1008. The system 1002 is medically useful in part because of its ability to control fluid flows involving solutes that are medicinal, nutritional and metabolically active. Biological tissue inherently functions as a cover membrane. Therefore, sealing the edges of the cover 1010 to healthy skin around the wound 1004 configures the system with the tissue layer 1005 comprising the lower enclosure, which cooperates with the cover 1010 to enclose the transducer component 1006. By way of example, steep gradients and rapid fluid flows can be achieved by constructing the layers of the system 1002 in such a way as to move accumulated concentrations of elements away from the base layer interface between the tissue 1005 and the transducer component 1006. Conversely, relatively high concentrations or pressures of desired elements can be achieved in a delivery mode of operation in order to affect high delivery rates to the tissue 1005. Tissue interaction can take the form of fluid absorption, exudation/transudation, exchange (solute/solvent), cellular response, and other physiological interactions.
Interconnecting base elements 1008 together inside of an interconnected second space environment attached to tissue can provide a device capable of expansion or contraction to fit multiple fluid flow needs for removal and delivery requirements for medical treatment of tissue of all sizes. The base element 1008 can range in size from gross macroscopic to molecular and nanometer, and tubule passage sizes can correspondingly cover a wide range for achieving desired fluid, pressure, gradient, biologic and other effects. Without limitation on the generality of useful applications of the present invention, it is anticipated that most of the desired fluid effects will occur utilizing passages and matrices in the micron to millimeter range.-
Gradients can be formed with various forces and interactions at different locations within the system 1002. For example, within the connector and tubing 1014, 1016 positive and negative pressures associated with external fluid and pressure sources can be formed. The outer surface of the cover 1010 forms an interface with the atmosphere or other environment external to the base element 1008. The inner surface of the cover 1010 forms an interface between the cover and the transducer component 1006. Within the transducer component 1006 pressure, osmotic, oncotic, chemical, biological, thermal and other gradients are formed. A transducer/tissue interface is formed between the transducer component 1006 and the tissue layer 1005. Finally, gradients are formed within the tissue layer 1005.
Another modified embodiment composite sheet panel system 1022 is shown in Figs. 23 and 23A and generally comprises a pair of perforated or semi-permeable sheets 1024 positioned in generally parallel, overlying relation with spot interconnections (e.g., spot welds) 1026, which can be suitably spaced for optimal performance. A pair of manifolds 1028 is provided along edges of the sheets 1024 for fluid introduction into or extraction out of an interstitial space 1030 comprising multiple, interconnected fluid passage pockets. Port assemblies 1032 for inflow and outflow are connected to the manifolds 1028 and can comprise Luer lock connectors, drain cocks, vents, sealing plugs, etc. for connection to the atmosphere or suitable sources of pressure and/or fluids, which can be chosen for particular patient indications. As shown in Fig. 23A, the central space 1030 can expand under positive pressure whereby multiple chambers and passages are formed between the sheets 1024 and the spot interconnections 1026. For example, fluid content to one of the ports 1032 can be dissipated throughout the wound, and fluid drainage can be accomplished through the other port 1032. The spot interconnections 1026 can restrain separation of the sheets 1024, which may be desirable when the central space 1030 is filled with larger volumes of pressurized fluid. The panel system 1022 can comprise various thin, flexible and durable materials, including polyurethane, cellulose, cellophane or rayon. Such materials are preferably chosen for their properties of permeability, i.e. membrane-like behavior for separating types of fluid on each side, and liquid adhesion involving their abilities to adhere to various liquids presented to the sheet 1024 surfaces and surface tension properties. The surfaces can optionally be coated with proteins and other materials affecting liquid adhesion. Hydrophobic and hydrophilic properties are also applicable to membrane-like performance. Additional performance-affecting construction material variables include the thickness and permeability of the sheets 1024. Still further, the size and spacing of the spot interconnections 1026 can vary considerably among systems embodying the present invention. For example, micro-systems with sub-centimeter spacing may be indicated for certain closure procedures, whereas macro systems with interconnections spaced several centimeters apart may be indicated for others. The manifolds 1028 and the ports 1032 can likewise have various sizes, configurations and locations. For example, the manifolds 1028 can be located on opposite edges, over-and- under along the same edge or along adjacent edges. The panel system 1022 can be provided as an elongated strip, which can be cut-to-length transversely for custom-fit installations.
The cut edges can be taped over or otherwise suitably closed. The ports 1032 can be fabricated with flexible tubing or other suitable materials, and can be fitted with various suitable connectors and terminations, including selectively closable sealing plugs at 1032.
Another modified embodiment composite sheet panel system 1042 is shown in Figs. 24 and 24A and includes a spacer matrix 1044 comprising multiple, individual spacers 1046 with generally flat, rectangular configurations extending between and providing a predetermined spacing between sheets 1048, thus defining a central space 1050. The spacers 1046 can be arranged to direct, restrict and otherwise control fluid flow under various conditions of pressure and flow rate. For example, by providing a sufficient number of spacers 1046 with sufficient rigidity, the sheets 1048 can be separated under negative pressure, thereby avoiding a flap-valve closure effect resulting from the application of negative pressure. Another modified embodiment composite sheet panel system 1052 is shown in Figs. 25 and 26 and includes a spacer matrix 1054 generally comprising multiple cylindrical spacers or tubules 1056 with opposite ends 1058 open at respective sheets 1060 whereby tubule passages 1062 provide additional surface area, which is exposed to fluid from both sides of the panel system 1052. This embodiment provides a relatively large exposed surface area, which facilitates pressure and fluid exchange between the system 1052 and the patient. The tubules 1056 can comprise similar materials to the sheets 1060, e.g. perforated or semi-permeable, or they can comprise different materials chosen for appropriate permeability and other characteristics. Fig. 26 shows the sheet panel system 1052 folded double and inserted into a wound for drawing the separated tissue portions together and for controlling fluid flow and pressure application in order to facilitate wound closure. The ports 1032 can apply positive or negative pressure and can inject or extract fluid. The operation of the closure system 1052 can be sequenced as appropriate, with predetermined durations for different phases of the wound treatment procedure. For example, positive and negative pressures can be alternately applied. Fluids, such as antibiotics, analgesics, anesthetics and growth factors can be applied in predetermined dosage levels for predetermined durations.
If the system is provided with a manifold, the added fluids or concentrations can be sequentially changed and varied as the changing environment of healing requires without changing the device or dressing. Oxygen can be applied intermittently for maximizing the benefits of topical hyperbaric therapy. Negative pressure can be utilized for extracting wound exudate and closing the wound edges. Another modified embodiment composite sheet panel system 1072 is shown in Fig. 27 and is similar to the panel system 1052, except that cylindrical spacers or ■ tubules 1074 thereof are closed at their respective ends by sheets 1076. Figs. 28, 28A and 28B show yet another modified embodiment composite sheet panel system 1082, which is similar to the system 1072 except that the cylindrical spacers 1074 are replaced with spheres 1084. The panel systems 1002, 1022, 1042, 1052, 1072 and 1082 are flexible and scalable and therefore can be formed in various configurations with different sizes and shapes. They can be premanufactured or trimmed-to-fit , as needed. Figs. 29 and 29A show another alternative embodiment construction of a composite sheet panel system 1092 with a pair of sheets 1094, each of which includes multiple hemispherical protrusions 1096, which are aligned with the sheets 1094 placed together to form multiple pockets 1097, which can be accessed by suitable manifolds and ports. As shown in Fig. 29A, the protrusions can be perforated with passages 1098 for communicating fluid with the pockets 1097. Fig. 30 shows another alternative embodiment composite sheet panel system 1102 with a sheet 1104, which can be similar to the sheets 1094, covered by a membrane 1106. Fig. 31 shows the composite sheet panel system 1092 in a wound with a transducer component 1006 placed in communication with the composite sheet panel system 1092 and located adjacent the skin surface. A membrane cover 1010 is placed over the transducer component 1006 and can be attached to a pressure source via a connector 1014 as described above. Another application of the composite sheet panel system 1092 is shown in Fig. 32 and includes a transducer component 1006 placed in the wound and partially surrounded by the composite sheet panel system 1092, with a cover 1010 placed thereover. Figs. 33 and 33A show a composite sheet panel system 1112 comprising another alternative embodiment of the invention with multiple, spherical pockets 1114 interconnected by a matrix of tubes 1116 for fluidic communication with external sources. Figs. 34 and 34A show another modified embodiment composite sheet panel system 1122 with disk-shaped pockets 1124 and passages 1126 positioned on both sides of a pocket matrix 1128 including interconnecting tubes 1130. Sheets 1132 are placed on both sides of the system 1122 and manifolds 1134 are located along respective edges in communication with the tubes 1130.
Figs. 35-36 show another alternative embodiment composite sheet panel system 1142 with an inner transducer component comprising a sheet 1144 with spherical protrusions 1146 defining outwardly-open pockets 1148. An intermediate transducer component 1150 is placed over the first transducer component 1144 and an outer transducer component 1152 with spherical elements 1153 is placed over the intermediate transducer component 1150. A cover 1110 is placed over the transducer components 1144, 1150, 1152 and can be connected to an external pressure source by a connector 1154 via tubing 1156. As shown in Fig. 36, the application of negative pressure tends to push the spherical elements 1153 of the outer transducer component 1152 into the pockets 1148 with the lateral transfer sheets 1150 therebetween whereby the fluids are dispersed through capillary and surface tension action. Fig. 37 shows a composite sheet panel system 1162 comprising a modified embodiment of the system 1142 with an opening 1164 formed in the outer transducer component 1152 for receiving a connector 1114 in contact with the lateral transfer sheet intermediate transducer component 1150. Juxtaposition of these shapes creates a controlled capillary space, which allows faster, more distal movement of fluid.
Fig. 38 shows another alternative embodiment wound treatment system 1172 with an inner transducer component comprising a layer of beads 1174 located generally under an outer transducer component 1176. The beads 1174 can comprise living cells, various pharmacological agents or a matrix for facilitating fluid and pressure transfer.
Figs 39 and 40 show another alternative embodiment wound treatment system 1182 with first and second sheets 1184 attached at disk-shaped connections 1186, which are similar to the spot welds 1026 described above, except with perforations 1188. In lieu of the multiple perforations 1188 shown, various sizes of single openings could be provided or the disk-shaped connections 1186 could be porous material.
Manifolds 1190 can be placed along the longitudinal and/or transverse edges of the sheets 1184 and connected to an external fluid and pressure sources as described above. The system 1182 can be placed between a transducer component 1006 and tissue 1005 whereby fluidic communication can occur through the perforations 1188. The sheets form pockets interconnected to form a fluid passage interstitial space 1192, which can be maintained with positive pressure, for example, to provide a smooth, uniform surface for clinical applications such as reepithelialization. XVI. Conclusion
It is to be understood that while certain forms of the present invention have been illustrated and described herein, it is not to be limited to the specific forms or arrangement of parts described and shown.
Furthermore, it should be appreciated that continuations, divisionals, and continuations-in-part applications depending from this specification may be pending at the time this patent issues, the claims of which may encompass embodiments and applications that are broader than the claims appended herein. Accordingly, embodiments or elements disclosed in the specification but not literally claimed in the appended claims, if any, should not be presumed to be dedicated to the public.

Claims

Claims
1. An osmotic transducer system, which includes: a base element including a transducer component adapted for fluidic communication with a wound and a cover adapted for placement over the transducer component; a central space formed by the cover and patient tissue structure, said transducer component being located in said central space; and an osmotic gradient formed with said base element and adapted for manipulating fluid elements whereby a pressure gradient is formed to produce useful fluid flow.
2. The system according to claim 1, which includes: said gradient being formed by the manipulation of osmotic, capillary, atmospheric and gas partial pressures.
3. The system according to claim 2 wherein said gradient is formed with externally-applied fluid pressure comprising either vacuum (negative) pressure or applied (positive) pressure. . . . .
4. The system according to claim 2, which includes: a pair of sheets positioned in generally parallel relation and including multiple spot connections whereat said sheets are fixedly attached to each other, said spot connections having configurations chosen from among the group comprising: impervious; semi-permeable; porous; and perforated; multiple, interconnected pockets formed between said sheets; said pockets forming a fluid passage interstitial space between said sheets; and a manifold connected to said sheets in communication with said interstitial space and an external pressure source.
5. The system according to claim 4, which includes: said connections being chosen from among the group comprising: sheet-to-sheet spot connections; spacers; tubules open at said sheet surfaces; tubules closed at said sheet surfaces; and spheres.
6. The system according to claim 4, which includes: said connections comprising multiple spheres connected to said sheets; and a matrix of tubes fluidically connecting said spheres and said manifold.
7. The system according to claim 4, which includes: a plurality of hollow disks; a matrix of tubes interconnecting said disks and said manifold; and a plurality of conduits placed over said disks and communicating with said manifold.
8. The system according to claim 2 wherein said transducer component comprises : a first transducer component including multiple, hemispherical protrusions forming outwardly-open pockets; an intermediate porous material layer placed over said first transducer component; and a second transducer component comprising a plurality of spherical elements interconnected to form a sheet.
9. The system according to claim 8, which includes: at least one of said hemispherical protrusions and said spherical elements being perforated.
10. The system according to claim 9, which includes: an opening formed in said second transducer component; and an external connector attached to said intermediate layer within said opening and adapted for' connection to an external pressure source.
11. The system according to claim 2 wherein said transducer component comprises: an inner transducer component including multiple, discrete beads chosen from among the group comprising pharmacologicals, growth factors, living cells and inert materials; and an outer pressure transducer comprising a foam material with hydrophobic or hydrophilic properties.
12. The system according to claim 2 wherein said cover has a configuration chosen from among the group comprising: impervious, semi-permeable and permeable.
13. The system according to claim 2, which includes: a vacuum source connected to said base element and forming a pressure gradient in said transducer component.
14. A gradient system for treating a wound, which system includes: an inner pressure transducer including first and second flexible sheets positioned in generally overlying relation and forming longitudinal and transverse inner pressure transducer edges; multiple spot connections fixedly interconnecting said first and second sheets and each including multiple perforations extending through said first and second sheets; said sheets forming multiple, interconnected pockets therebetween whereat said sheets are adapted for separation under positive fluid pressure and said pockets define a fluid passage interstitial space between said sheets ; first and second manifolds attached to said first and second sheets along respective inner pressure transducer edges, said manifolds fluidically communicating with said pockets along respective said inner pressure transducer edges and each including an inlet/outlet port; an outer pressure transducer comprising a porous foam material forming capillary, osmotic and atmospheric pressure gradients; said outer pressure transducer being located over said inner pressure transducer in fluidic communication therewith; a flexible cover placed over said outer pressure transducer and including a perimeter adapted for a adhesively securing to a patient around said wound; said inner and outer pressure transducers and said cover forming a base element with a central space generally enclosed by said cover and patient tissue; said manifolds extending through said central space and terminating externally of said cover; and an external pressure source connected to said manifolds and adapted for providing positive and negative pressure to said base element through said manifolds.
15. A wound treatment and closure method, which comprises the steps of: providing a base element with a transducer component and a cover; placing said transducer component in communication with tissue in said wound; placing said cover over said transducer component in contact with skin surface around said wound; establishing a gradient with respect to said wound, said transducer component and said cover; and directing fluid flow to or from said tissue by controlling pressures associated with said gradient.
16. The method according to claim 15, which includes the additional steps of: establishing osmotic, capillary, atmospheric and gas partial gradients with respect to said wound, said transducer component and said cover.
17. The method according to claim.15/ which includes the additional step of externally applying fluid pressure comprising either vacuum (negative) pressure or applied (positive) pressure from an external fluid pressure ' source .
18. The method according to claim 17, which includes the additional steps of: providing said pressure transducer with a manifold; and connecting said manifold to said external fluid pressure source.
19. The method according to claim 18, which includes the additional steps of: forming said pressure transducer with first and second sheets; connecting said sheets in overlying relation at multiple spot connections; and forming multiple pockets between said sheets and interconnecting said pockets to form a fluid passage interstitial space between said sheets.
20. The method according to claim 19, which includes the additional step of: forming said spot connections with configurations chosen from the group comprising: sheet-to-sheet spot connections; spacers; tubules open at said sheet surfaces; tubules closed at said sheet surfaces; and spheres .
21. The method according to claim 19, which includes the additional step of: fixedly attaching said sheets to each other at said spot connections; forming said spot connections with configurations chosen from among the group comprising: impervious; semipermeable; porous; and perforated.
22. The method according to claim 21, which includes the additional steps of: providing first and second manifolds; connecting said manifolds to said sheets in communication with said interstitial space; providing an external pressure source; and providing negative (vacuum) and positive (applied) pressures to said interstitial space from said external pressure source.
23. The method according to claim 15, which includes the additional steps of: providing a second cover; and placing said second cover in overlying relation over said first cover.
24. The method according to claim 15, which includes the additional step of: forming said pressure transducer with a hydrophilic or hydrophobic foam material .
25. The method according to claim 24, which includes the additional steps of: forming a first pressure transducer component with said foam material; providing a second pressure transducer component including multiple, discrete beads chosen from among the group comprising pharmacologicals, growth factors, living cells and inert materials; and forming a pressure gradient between said first and second pressure transducers.
PCT/US2007/018767 2006-09-19 2007-08-24 Gradient wound treatment system and method WO2008036162A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/523,672 US7645269B2 (en) 2001-04-30 2006-09-19 Gradient wound treatment system and method
US11/523,672 2006-09-19

Publications (2)

Publication Number Publication Date
WO2008036162A2 true WO2008036162A2 (en) 2008-03-27
WO2008036162A3 WO2008036162A3 (en) 2008-09-04

Family

ID=39201032

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018767 WO2008036162A2 (en) 2006-09-19 2007-08-24 Gradient wound treatment system and method

Country Status (2)

Country Link
US (1) US7645269B2 (en)
WO (1) WO2008036162A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8702711B2 (en) 2008-12-30 2014-04-22 Kci Licensing, Inc. Reduced pressure augmentation of microfracture procedures for cartilage repair
EP2848268A1 (en) 2008-12-31 2015-03-18 KCI Licensing, Inc. Tissue roll scaffolds
US9033942B2 (en) 2008-03-07 2015-05-19 Smith & Nephew, Inc. Wound dressing port and associated wound dressing
US9050398B2 (en) 2010-12-22 2015-06-09 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US9227000B2 (en) 2006-09-28 2016-01-05 Smith & Nephew, Inc. Portable wound therapy system
US9642750B2 (en) 2009-12-22 2017-05-09 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
WO2017119996A1 (en) * 2016-01-06 2017-07-13 Kci Liecensing, Inc. System and methods for the treatment of wounds with dressing having closed cells
US9801761B2 (en) 2010-07-02 2017-10-31 Smith & Nephew Plc Provision of wound filler
USD804014S1 (en) 2010-12-22 2017-11-28 Smith & Nephew, Inc. Suction adapter
US10406036B2 (en) 2009-06-18 2019-09-10 Smith & Nephew, Inc. Apparatus for vacuum bridging and/or exudate collection
US10537657B2 (en) 2010-11-25 2020-01-21 Smith & Nephew Plc Composition I-II and products and uses thereof
USRE48117E1 (en) 2010-05-07 2020-07-28 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US11638666B2 (en) 2011-11-25 2023-05-02 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US11931226B2 (en) 2013-05-30 2024-03-19 Smith & Nephew Plc Wound dressing sealant and use thereof

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458109B1 (en) * 1998-08-07 2002-10-01 Hill-Rom Services, Inc. Wound treatment apparatus
US6764462B2 (en) 2000-11-29 2004-07-20 Hill-Rom Services Inc. Wound treatment apparatus
US6824533B2 (en) * 2000-11-29 2004-11-30 Hill-Rom Services, Inc. Wound treatment apparatus
ATE407647T1 (en) 2000-05-22 2008-09-15 Arthur C Coffey WOUND DRESSING WITH SIS LAYER AND VACUUM CHAMBER
US6685681B2 (en) * 2000-11-29 2004-02-03 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
US6855135B2 (en) 2000-11-29 2005-02-15 Hill-Rom Services, Inc. Vacuum therapy and cleansing dressing for wounds
EP1450878A1 (en) * 2001-10-11 2004-09-01 Hill-Rom Services, Inc. Waste container for negative pressure therapy
US7534927B2 (en) * 2001-12-26 2009-05-19 Hill-Rom Services, Inc. Vacuum bandage packing
WO2003057307A1 (en) 2001-12-26 2003-07-17 Hill-Rom Services, Inc. Wound vacuum therapy dressing kit
EP1478313B2 (en) 2001-12-26 2018-03-07 KCI Medical Resources Vented vacuum bandage
US8168848B2 (en) 2002-04-10 2012-05-01 KCI Medical Resources, Inc. Access openings in vacuum bandage
US7896856B2 (en) * 2002-08-21 2011-03-01 Robert Petrosenko Wound packing for preventing wound closure
GB0224986D0 (en) 2002-10-28 2002-12-04 Smith & Nephew Apparatus
US10363344B2 (en) 2002-12-31 2019-07-30 Kci Licensing, Inc. Externally-applied patient interface system and method with a controlled region for implanted or buried bio-reactor
US11298453B2 (en) 2003-10-28 2022-04-12 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
US8758313B2 (en) * 2003-10-28 2014-06-24 Smith & Nephew Plc Apparatus and method for wound cleansing with actives
GB0518826D0 (en) * 2005-09-15 2005-10-26 Smith & Nephew Apparatus with actives from tissue - exudialysis
GB0518804D0 (en) * 2005-09-15 2005-10-26 Smith & Nephew Exudialysis tissue cleanser
GB0518825D0 (en) * 2005-09-15 2005-10-26 Smith & Nephew Apparatus with actives from tissue - sai
GB0325120D0 (en) * 2003-10-28 2003-12-03 Smith & Nephew Apparatus with actives
GB0325130D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with scaffold
GB0325129D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus in situ
GB0325126D0 (en) 2003-10-28 2003-12-03 Smith & Nephew Apparatus with heat
GB0409443D0 (en) * 2004-04-28 2004-06-02 Smith & Nephew Apparatus
US7708724B2 (en) * 2004-04-05 2010-05-04 Blue Sky Medical Group Incorporated Reduced pressure wound cupping treatment system
US7776028B2 (en) 2004-04-05 2010-08-17 Bluesky Medical Group Incorporated Adjustable overlay reduced pressure wound treatment system
US8062272B2 (en) 2004-05-21 2011-11-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US10058642B2 (en) 2004-04-05 2018-08-28 Bluesky Medical Group Incorporated Reduced pressure treatment system
US7909805B2 (en) 2004-04-05 2011-03-22 Bluesky Medical Group Incorporated Flexible reduced pressure treatment appliance
US7951124B2 (en) * 2004-04-13 2011-05-31 Boehringer Technologies, Lp Growth stimulating wound dressing with improved contact surfaces
GB0424046D0 (en) 2004-10-29 2004-12-01 Smith & Nephew Apparatus
GB0409444D0 (en) * 2004-04-28 2004-06-02 Smith & Nephew Apparatus
GB0409446D0 (en) * 2004-04-28 2004-06-02 Smith & Nephew Apparatus
US8529548B2 (en) 2004-04-27 2013-09-10 Smith & Nephew Plc Wound treatment apparatus and method
GB0508528D0 (en) * 2005-04-27 2005-06-01 Smith & Nephew SAI with macrostress
GB0508529D0 (en) * 2005-04-27 2005-06-01 Smith & Nephew Sai with microstress
GB0508531D0 (en) * 2005-04-27 2005-06-01 Smith & Nephew Sai with ultrasound
US7753894B2 (en) 2004-04-27 2010-07-13 Smith & Nephew Plc Wound cleansing apparatus with stress
SE0500061L (en) 2005-01-11 2006-07-12 Moelnlycke Health Care Ab Sealing film dressing
CN101257875A (en) 2005-09-06 2008-09-03 泰科保健集团有限合伙公司 Self contained wound dressing with micropump
WO2007087810A2 (en) * 2006-02-02 2007-08-09 Coloplast A/S A suction method and a wound suction system
US7779625B2 (en) 2006-05-11 2010-08-24 Kalypto Medical, Inc. Device and method for wound therapy
WO2009098696A2 (en) * 2008-02-10 2009-08-13 Empire Bio-Medical Devices Inc. Device and method for enhanced wound treatment
SE0601536L (en) * 2006-07-11 2008-01-12 Moelnlycke Health Care Ab Coil connection
US7758476B2 (en) * 2007-02-06 2010-07-20 Fitness Botics Inflatable cushion bag for striking
SG192307A1 (en) 2007-02-09 2013-08-30 Kci Licensing Inc A breathable interface system for topical reduced pressure
GB0712763D0 (en) 2007-07-02 2007-08-08 Smith & Nephew Apparatus
GB0712739D0 (en) 2007-07-02 2007-08-08 Smith & Nephew Apparatus
GB0712764D0 (en) 2007-07-02 2007-08-08 Smith & Nephew Carrying Bag
US7790946B2 (en) * 2007-07-06 2010-09-07 Tyco Healthcare Group Lp Subatmospheric pressure wound therapy dressing
US8246590B2 (en) * 2007-10-11 2012-08-21 Spiracur, Inc. Closed incision negative pressure wound therapy device and methods of use
GB0722820D0 (en) 2007-11-21 2008-01-02 Smith & Nephew Vacuum assisted wound dressing
US8808259B2 (en) 2007-11-21 2014-08-19 T.J. Smith & Nephew Limited Suction device and dressing
CN101883546B (en) 2007-11-21 2017-05-10 史密夫及内修公开有限公司 Wound dressing
EP3254650B1 (en) 2007-11-21 2020-01-08 Smith & Nephew plc Wound dressing
GB0723872D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Apparatus for topical negative pressure therapy
GB0723875D0 (en) 2007-12-06 2008-01-16 Smith & Nephew Wound management
GB2455962A (en) 2007-12-24 2009-07-01 Ethicon Inc Reinforced adhesive backing sheet, for plaster
DK2242522T3 (en) 2008-01-08 2012-06-18 Bluesky Medical Group Inc Wound treatment with uninterrupted variable pressure and methods for controlling it
CN101959480B (en) 2008-03-05 2013-06-05 凯希特许有限公司 Dressing and method for applying reduced pressure to and collecting and storing fluid from a tissue site
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US8021347B2 (en) 2008-07-21 2011-09-20 Tyco Healthcare Group Lp Thin film wound dressing
AU2009223037A1 (en) 2008-03-12 2009-09-17 Smith & Nephew Plc Negative pressure dressing and method of using same
US8211053B2 (en) * 2008-05-13 2012-07-03 Equilibrate, Llc Interosmolar fluid removal
KR101567619B1 (en) * 2008-05-21 2015-11-10 모리스 토파즈 Wound healing device
AU2009251810B2 (en) * 2008-05-27 2013-03-28 Smith & Nephew, Inc. Negative pressure wound therapy device
EP2288321B1 (en) * 2008-05-27 2019-10-23 Smith & Nephew, Inc. Control unit with pump module for a negative pressure wound therapy device
SE532493C2 (en) * 2008-05-29 2010-02-09 Moelnlycke Health Care Ab Wound dressing with two interconnected wound pads, suitable for use with compression dressings
US20100036334A1 (en) 2008-08-08 2010-02-11 Tyco Healthcare Group Lp Wound Dressing of Continuous Fibers
US8162907B2 (en) 2009-01-20 2012-04-24 Tyco Healthcare Group Lp Method and apparatus for bridging from a dressing in negative pressure wound therapy
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
US8444614B2 (en) * 2009-04-10 2013-05-21 Spiracur, Inc. Methods and devices for applying closed incision negative pressure wound therapy
EP2905037B1 (en) 2009-04-10 2017-05-17 KCI Licensing, Inc. Devices for applying closed incision negative pressure wound therapy
EP2419157A4 (en) 2009-04-17 2018-01-03 Kalypto Medical, Inc. Negative pressure wound therapy device
SE533726C2 (en) * 2009-04-30 2010-12-14 Moelnlycke Health Care Ab Apparatus with negative pressure for treatment of wounds
WO2011017489A1 (en) 2009-08-05 2011-02-10 Tyco Healthcare Group Lp Surgical wound dressing incorporating connected hydrogel beads having an embedded electrode therein
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
US8721606B2 (en) * 2010-03-11 2014-05-13 Kci Licensing, Inc. Dressings, systems, and methods for treating a tissue site
US8814842B2 (en) 2010-03-16 2014-08-26 Kci Licensing, Inc. Delivery-and-fluid-storage bridges for use with reduced-pressure systems
WO2011121482A2 (en) * 2010-03-31 2011-10-06 Koninklijke Philips Electronics N.V. Wound care system
US8821458B2 (en) * 2010-04-16 2014-09-02 Kci Licensing, Inc. Evaporative body-fluid containers and methods
US9061095B2 (en) 2010-04-27 2015-06-23 Smith & Nephew Plc Wound dressing and method of use
USD692565S1 (en) 2010-06-03 2013-10-29 Smith & Nephew, Inc. Organ protection layer
CA140188S (en) 2010-10-15 2011-11-07 Smith & Nephew Medical dressing
CA140189S (en) 2010-10-15 2011-11-07 Smith & Nephew Medical dressing
WO2013007973A2 (en) 2011-07-14 2013-01-17 Smith & Nephew Plc Wound dressing and method of treatment
GB2488749A (en) 2011-01-31 2012-09-12 Systagenix Wound Man Ip Co Bv Laminated silicone coated wound dressing
AU2012212070A1 (en) 2011-02-04 2013-09-19 University Of Massachusetts Negative pressure wound closure device
US9421132B2 (en) 2011-02-04 2016-08-23 University Of Massachusetts Negative pressure wound closure device
GB201106491D0 (en) 2011-04-15 2011-06-01 Systagenix Wound Man Ip Co Bv Patterened silicone coating
AU2011366180B2 (en) * 2011-04-21 2016-04-21 Smith & Nephew Plc Blockage management
CN103842000A (en) 2011-05-24 2014-06-04 卡利普托医疗公司 Device with controller and pump modules for providing negative pressure for wound therapy
US9058634B2 (en) 2011-05-24 2015-06-16 Kalypto Medical, Inc. Method for providing a negative pressure wound therapy pump device
US9067003B2 (en) 2011-05-26 2015-06-30 Kalypto Medical, Inc. Method for providing negative pressure to a negative pressure wound therapy bandage
IN2014CN02072A (en) * 2011-08-22 2015-05-29 Microlin Llc
US9569566B2 (en) * 2011-12-12 2017-02-14 Zam Research Llc Simulation and control system and method using contact, pressure waves and factor controls for cell regeneration, tissue closure and related applications
CN103987348B (en) 2011-12-16 2016-05-11 凯希特许有限公司 Releasable medical cloth list
US10940047B2 (en) 2011-12-16 2021-03-09 Kci Licensing, Inc. Sealing systems and methods employing a hybrid switchable drape
AU346291S (en) 2012-05-15 2013-01-09 Smith & Nephew Medical dressing
CN107280857A (en) 2012-05-22 2017-10-24 史密夫及内修公开有限公司 Wound healing device
CN104661601B (en) 2012-05-22 2018-06-22 史密夫及内修公开有限公司 For the device and method of Wound healing and bone regeneration
EP3354293B1 (en) 2012-05-23 2019-12-11 Smith & Nephew plc Apparatuses for negative pressure wound therapy
EP3470029A1 (en) 2012-05-24 2019-04-17 Smith & Nephew, Inc. Devices for treating and closing wounds with negative pressure
FR2990861B1 (en) * 2012-05-25 2015-07-17 Apex Medical Corp NEGATIVE PRESSURE WOUND TREATMENT SYSTEM HAVING A BUFFER UNIT
AU2013290346B2 (en) 2012-07-16 2018-06-07 Smith & Nephew, Inc. Negative pressure wound closure device
CA3178997A1 (en) 2012-08-01 2014-02-06 Smith & Nephew Plc Wound dressing
WO2014020443A2 (en) 2012-08-01 2014-02-06 Smith & Nephew Pcl Wound dressing and method of treatment
EP2915558A4 (en) * 2012-10-31 2016-08-10 Univ Tokyo Womens Medical Sheet shaped therapeutic-use substance conveyance apparatus, and method for affixing sheet shaped therapeutic-use substance
US9968488B2 (en) 2012-11-12 2018-05-15 Kci Usa, Inc. Externally-applied patient interface system and method
EP4279094A3 (en) 2012-11-16 2024-02-28 3M Innovative Properties Company Medical drape with pattern adhesive layers
GB201222770D0 (en) 2012-12-18 2013-01-30 Systagenix Wound Man Ip Co Bv Wound dressing with adhesive margin
WO2014137824A1 (en) * 2013-03-07 2014-09-12 Life Sciences Llc Apparatus & method for wound infection prevention
MX369065B (en) 2013-03-13 2019-10-28 Smith & Nephew Inc Negative pressure wound closure device and systems and methods of use in treating wounds with negative pressure.
US9737649B2 (en) 2013-03-14 2017-08-22 Smith & Nephew, Inc. Systems and methods for applying reduced pressure therapy
AU2014236701B2 (en) * 2013-03-14 2018-07-19 Smith & Nephew Inc. Systems and methods for applying reduced pressure therapy
USD764654S1 (en) 2014-03-13 2016-08-23 Smith & Nephew, Inc. Canister for collecting wound exudate
CN105007870B (en) 2013-03-14 2019-12-13 史密夫及内修公开有限公司 Compressible wound fillers, systems and methods for use in treating wounds with negative pressure
EP3238674B1 (en) 2013-03-14 2019-01-30 KCI Licensing, Inc. Absorbent dressing with hybrid drape
US10492956B2 (en) 2013-03-15 2019-12-03 Kci Licensing, Inc. Topical vacuum-press surgical incisional dressings, surgical adjuncts, hybrids and composites
WO2014145993A2 (en) 2013-03-15 2014-09-18 Kci Licensing Inc. Topical vacuum-press surgical incisional dressings, surgical adjuncts, hybrids and composites
US8893721B2 (en) 2013-03-15 2014-11-25 Futrell Medical Corporation Surgical drape with vapor evacuation
BR112015027696A2 (en) 2013-05-10 2017-08-29 Smith & Nephew FLUID CONNECTOR FOR IRRIGATION AND ASPIRATION OF WOUNDS
EP3038667B1 (en) 2013-08-26 2019-10-09 KCI Licensing, Inc. Dressing interface with moisture controlling feature and sealing function
EP3060181B1 (en) 2013-10-21 2021-11-03 Smith & Nephew, Inc. Negative pressure wound closure device
US10946124B2 (en) 2013-10-28 2021-03-16 Kci Licensing, Inc. Hybrid sealing tape
US9925092B2 (en) 2013-10-30 2018-03-27 Kci Licensing, Inc. Absorbent conduit and system
US9956120B2 (en) 2013-10-30 2018-05-01 Kci Licensing, Inc. Dressing with sealing and retention interface
EP3513773A1 (en) 2013-10-30 2019-07-24 KCI Licensing, Inc. Condensate absorbing and dissipating system
WO2015065614A1 (en) 2013-10-30 2015-05-07 Kci Licensing, Inc. Dressing with differentially sized perforations
EP4008299A1 (en) 2014-01-21 2022-06-08 Smith & Nephew PLC Collapsible dressing for negative pressure wound treatment
EP3848009A1 (en) 2014-02-28 2021-07-14 3M Innovative Properties Company Hybrid drape having a gel-coated perforated mesh
US11026844B2 (en) 2014-03-03 2021-06-08 Kci Licensing, Inc. Low profile flexible pressure transmission conduit
US10406266B2 (en) 2014-05-02 2019-09-10 Kci Licensing, Inc. Fluid storage devices, systems, and methods
USD764048S1 (en) 2014-05-28 2016-08-16 Smith & Nephew, Inc. Device for applying negative pressure to a wound
USD764047S1 (en) 2014-05-28 2016-08-16 Smith & Nephew, Inc. Therapy unit assembly
USD764653S1 (en) 2014-05-28 2016-08-23 Smith & Nephew, Inc. Canister for collecting wound exudate
USD770173S1 (en) 2014-06-02 2016-11-01 Smith & Nephew, Inc. Bag
USD765830S1 (en) 2014-06-02 2016-09-06 Smith & Nephew, Inc. Therapy unit assembly
AU2015269359B2 (en) 2014-06-05 2019-08-15 Kci Licensing, Inc. Dressing with fluid acquisition and distribution characteristics
EP3233001B1 (en) 2014-12-17 2020-06-17 KCI Licensing, Inc. Dressing with offloading capability
AU2016254119A1 (en) 2015-04-29 2017-10-05 Smith & Nephew Inc. Negative pressure wound closure device
EP3294245B1 (en) * 2015-05-08 2019-09-04 KCI Licensing, Inc. Low acuity dressing with integral pump
US10076594B2 (en) 2015-05-18 2018-09-18 Smith & Nephew Plc Fluidic connector for negative pressure wound therapy
US10583228B2 (en) 2015-07-28 2020-03-10 J&M Shuler Medical, Inc. Sub-atmospheric wound therapy systems and methods
WO2017040045A1 (en) 2015-09-01 2017-03-09 Kci Licensing, Inc. Dressing with increased apposition force
US10973694B2 (en) 2015-09-17 2021-04-13 Kci Licensing, Inc. Hybrid silicone and acrylic adhesive cover for use with wound treatment
US10575991B2 (en) 2015-12-15 2020-03-03 University Of Massachusetts Negative pressure wound closure devices and methods
US10814049B2 (en) 2015-12-15 2020-10-27 University Of Massachusetts Negative pressure wound closure devices and methods
US11471586B2 (en) 2015-12-15 2022-10-18 University Of Massachusetts Negative pressure wound closure devices and methods
GB2555584B (en) 2016-10-28 2020-05-27 Smith & Nephew Multi-layered wound dressing and method of manufacture
EP3592400A4 (en) * 2017-03-09 2020-11-25 Secretary, Department Of Biotechnology A wound dressing for combined negative pressure and fluid delivery system
IT201700042114A1 (en) * 2017-04-14 2018-10-14 Humana Medical S R L Medical device for the treatment of wounds
US11607342B2 (en) 2017-06-07 2023-03-21 Kci Licensing, Inc. Peel and place dressing for negative-pressure therapy
WO2018226627A1 (en) 2017-06-07 2018-12-13 Kci Licensing, Inc. Composite dressings for improved granulation and reduced maceration with negative-pressure treatment
CN110868969B (en) 2017-06-07 2022-01-11 3M创新知识产权公司 Composite dressing for improving granulation growth and reducing maceration by negative pressure therapy
CN110831552B (en) * 2017-06-07 2022-06-10 3M创新知识产权公司 Multilayered wound filler with extended wear time
US11207217B2 (en) 2017-06-07 2021-12-28 Kci Licensing, Inc. Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy
KR20200016934A (en) 2017-06-07 2020-02-17 케이씨아이 라이센싱 인코포레이티드 Composite dressing for improving childcare and reducing smoke by using negative pressure treatment
WO2018226687A1 (en) 2017-06-07 2018-12-13 Kci Licensing, Inc. Methods for manufacturing and assembling dual material tissue interface for negative-pressure therapy
US11471332B2 (en) 2017-06-07 2022-10-18 Kci Licensing, Inc. Systems, apparatuses, and methods for negative-pressure treatment with reduced tissue in-growth
RU2019140648A (en) 2017-06-07 2021-07-12 Кейсиай ЛАЙСЕНСИНГ, ИНК. Composite Dressings for Improved Granulation and Reduced Maceration for Negative Pressure Treatment
EP3638173A1 (en) 2017-06-14 2020-04-22 Smith & Nephew, Inc Control of wound closure and fluid removal management in wound therapy
AU2018284233B2 (en) * 2017-06-14 2024-01-04 Smith & Nephew, Inc. Fluid removal management and control of wound closure in wound therapy
GB201718014D0 (en) 2017-11-01 2017-12-13 Smith & Nephew Dressing for negative pressure wound therapy with filter
US11511032B2 (en) * 2018-03-12 2022-11-29 Kci Licensing, Inc. Dressing using differential surface features for use in compartment spaces
GB201811449D0 (en) 2018-07-12 2018-08-29 Smith & Nephew Apparatuses and methods for negative pressure wound therapy
KR102628722B1 (en) * 2019-06-20 2024-01-24 쿠오후앙 양 Fluid retention/retention pad
US11160917B2 (en) 2020-01-22 2021-11-02 J&M Shuler Medical Inc. Negative pressure wound therapy barrier

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382441A (en) * 1978-12-06 1983-05-10 Svedman Paul Device for treating tissues, for example skin
US5678564A (en) * 1992-08-07 1997-10-21 Bristol Myers Squibb Liquid removal system
US6071267A (en) * 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method
US6398767B1 (en) * 1997-05-27 2002-06-04 Wilhelm Fleischmann Process and device for application of active substances to a wound surface area

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1355846A (en) 1920-02-06 1920-10-19 David A Rannells Medical appliance
US2547758A (en) 1949-01-05 1951-04-03 Wilmer B Keeling Instrument for treating the male urethra
US2632443A (en) 1949-04-18 1953-03-24 Eleanor P Lesher Surgical dressing
GB692578A (en) 1949-09-13 1953-06-10 Minnesota Mining & Mfg Improvements in or relating to drape sheets for surgical use
US2682873A (en) 1952-07-30 1954-07-06 Johnson & Johnson General purpose protective dressing
US2969057A (en) 1957-11-04 1961-01-24 Brady Co W H Nematodic swab
US3066672A (en) 1960-09-27 1962-12-04 Jr William H Crosby Method and apparatus for serial sampling of intestinal juice
US3367332A (en) 1965-08-27 1968-02-06 Gen Electric Product and process for establishing a sterile area of skin
US3520300A (en) 1967-03-15 1970-07-14 Amp Inc Surgical sponge and suction device
US3682180A (en) 1970-06-08 1972-08-08 Coilform Co Inc Drain clip for surgical drain
BE789293Q (en) 1970-12-07 1973-01-15 Parke Davis & Co MEDICO-SURGICAL DRESSING FOR BURNS AND SIMILAR LESIONS
US3880164A (en) * 1972-05-22 1975-04-29 Alza Corp Osmotic wound drain
US3826254A (en) 1973-02-26 1974-07-30 Verco Ind Needle or catheter retaining appliance
DE2527706A1 (en) 1975-06-21 1976-12-30 Hanfried Dr Med Weigand DEVICE FOR THE INTRODUCTION OF CONTRAST AGENTS INTO AN ARTIFICIAL INTESTINAL OUTLET
DE2640413C3 (en) 1976-09-08 1980-03-27 Richard Wolf Gmbh, 7134 Knittlingen Catheter monitor
NL7710909A (en) 1976-10-08 1978-04-11 Smith & Nephew COMPOSITE STRAPS.
GB1562244A (en) 1976-11-11 1980-03-05 Lock P M Wound dressing materials
US4080970A (en) 1976-11-17 1978-03-28 Miller Thomas J Post-operative combination dressing and internal drain tube with external shield and tube connector
US4139004A (en) 1977-02-17 1979-02-13 Gonzalez Jr Harry Bandage apparatus for treating burns
US4165748A (en) 1977-11-07 1979-08-28 Johnson Melissa C Catheter tube holder
SE414994B (en) 1978-11-28 1980-09-01 Landstingens Inkopscentral VENKATETERFORBAND
US4284079A (en) 1979-06-28 1981-08-18 Adair Edwin Lloyd Method for applying a male incontinence device
US4261363A (en) 1979-11-09 1981-04-14 C. R. Bard, Inc. Retention clips for body fluid drains
US4569348A (en) 1980-02-22 1986-02-11 Velcro Usa Inc. Catheter tube holder strap
EP0035583B1 (en) 1980-03-11 1985-08-14 Schmid, Eduard, Dr.Dr.med. Skin graft pressure bandage
US4297995A (en) 1980-06-03 1981-11-03 Key Pharmaceuticals, Inc. Bandage containing attachment post
US4333468A (en) 1980-08-18 1982-06-08 Geist Robert W Mesentery tube holder apparatus
US4392853A (en) 1981-03-16 1983-07-12 Rudolph Muto Sterile assembly for protecting and fastening an indwelling device
US4373519A (en) 1981-06-26 1983-02-15 Minnesota Mining And Manufacturing Company Composite wound dressing
US4392858A (en) 1981-07-16 1983-07-12 Sherwood Medical Company Wound drainage device
US4419097A (en) 1981-07-31 1983-12-06 Rexar Industries, Inc. Attachment for catheter tube
AU550575B2 (en) 1981-08-07 1986-03-27 Richard Christian Wright Wound drainage device
SE429197B (en) 1981-10-14 1983-08-22 Frese Nielsen SAR TREATMENT DEVICE
DE3146266A1 (en) 1981-11-21 1983-06-01 B. Braun Melsungen Ag, 3508 Melsungen COMBINED DEVICE FOR A MEDICAL SUCTION DRAINAGE
US4551139A (en) 1982-02-08 1985-11-05 Marion Laboratories, Inc. Method and apparatus for burn wound treatment
US4475909A (en) 1982-05-06 1984-10-09 Eisenberg Melvin I Male urinary device and method for applying the device
EP0100148B1 (en) 1982-07-06 1986-01-08 Dow Corning Limited Medical-surgical dressing and a process for the production thereof
NZ206837A (en) 1983-01-27 1986-08-08 Johnson & Johnson Prod Inc Thin film adhesive dressing:backing material in three sections
US4548202A (en) 1983-06-20 1985-10-22 Ethicon, Inc. Mesh tissue fasteners
US4540412A (en) 1983-07-14 1985-09-10 The Kendall Company Device for moist heat therapy
US4543100A (en) 1983-11-01 1985-09-24 Brodsky Stuart A Catheter and drain tube retainer
US4525374A (en) 1984-02-27 1985-06-25 Manresa, Inc. Treating hydrophobic filters to render them hydrophilic
GB2157958A (en) 1984-05-03 1985-11-06 Ernest Edward Austen Bedding Ball game net support
US4897081A (en) 1984-05-25 1990-01-30 Thermedics Inc. Percutaneous access device
US5215522A (en) 1984-07-23 1993-06-01 Ballard Medical Products Single use medical aspirating device and method
US4872450A (en) 1984-08-17 1989-10-10 Austad Eric D Wound dressing and method of forming same
US4655754A (en) 1984-11-09 1987-04-07 Stryker Corporation Vacuum wound drainage system and lipids baffle therefor
US4826494A (en) 1984-11-09 1989-05-02 Stryker Corporation Vacuum wound drainage system
US4605399A (en) 1984-12-04 1986-08-12 Complex, Inc. Transdermal infusion device
US5037397A (en) 1985-05-03 1991-08-06 Medical Distributors, Inc. Universal clamp
US4640688A (en) 1985-08-23 1987-02-03 Mentor Corporation Urine collection catheter
US4710165A (en) 1985-09-16 1987-12-01 Mcneil Charles B Wearable, variable rate suction/collection device
US4758220A (en) 1985-09-26 1988-07-19 Alcon Laboratories, Inc. Surgical cassette proximity sensing and latching apparatus
US4733659A (en) 1986-01-17 1988-03-29 Seton Company Foam bandage
US4838883A (en) 1986-03-07 1989-06-13 Nissho Corporation Urine-collecting device
JPS62281965A (en) 1986-05-29 1987-12-07 テルモ株式会社 Catheter and catheter fixing member
GB8621884D0 (en) 1986-09-11 1986-10-15 Bard Ltd Catheter applicator
US4743232A (en) 1986-10-06 1988-05-10 The Clinipad Corporation Package assembly for plastic film bandage
DE3634569A1 (en) 1986-10-10 1988-04-21 Sachse Hans E CONDOM CATHETER, A URINE TUBE CATHETER FOR PREVENTING RISING INFECTIONS
JPS63135179A (en) 1986-11-26 1988-06-07 立花 俊郎 Subcataneous drug administration set
GB8628564D0 (en) 1986-11-28 1987-01-07 Smiths Industries Plc Anti-foaming agent suction apparatus
GB8706116D0 (en) 1987-03-14 1987-04-15 Smith & Nephew Ass Adhesive dressings
US4787888A (en) 1987-06-01 1988-11-29 University Of Connecticut Disposable piezoelectric polymer bandage for percutaneous delivery of drugs and method for such percutaneous delivery (a)
US4863449A (en) 1987-07-06 1989-09-05 Hollister Incorporated Adhesive-lined elastic condom cathether
US5176663A (en) 1987-12-02 1993-01-05 Pal Svedman Dressing having pad with compressibility limiting elements
US4906240A (en) 1988-02-01 1990-03-06 Matrix Medica, Inc. Adhesive-faced porous absorbent sheet and method of making same
US4985019A (en) 1988-03-11 1991-01-15 Michelson Gary K X-ray marker
GB8812803D0 (en) 1988-05-28 1988-06-29 Smiths Industries Plc Medico-surgical containers
US4919654A (en) 1988-08-03 1990-04-24 Kalt Medical Corporation IV clamp with membrane
US5000741A (en) 1988-08-22 1991-03-19 Kalt Medical Corporation Transparent tracheostomy tube dressing
EP0379416B1 (en) 1989-01-16 1995-03-08 Roussel-Uclaf Azabicycloheptene derivatives and their salts, process for their preparation, their use as medicaments and compositions containing them
US5261893A (en) 1989-04-03 1993-11-16 Zamierowski David S Fastening system and method
US4969880A (en) 1989-04-03 1990-11-13 Zamierowski David S Wound dressing and treatment method
US5527293A (en) 1989-04-03 1996-06-18 Kinetic Concepts, Inc. Fastening system and method
US5100396A (en) 1989-04-03 1992-03-31 Zamierowski David S Fluidic connection system and method
US5358494A (en) 1989-07-11 1994-10-25 Svedman Paul Irrigation dressing
JP2719671B2 (en) 1989-07-11 1998-02-25 日本ゼオン株式会社 Wound dressing
US5232453A (en) 1989-07-14 1993-08-03 E. R. Squibb & Sons, Inc. Catheter holder
GB2235877A (en) 1989-09-18 1991-03-20 Antonio Talluri Closed wound suction apparatus
US5152757A (en) * 1989-12-14 1992-10-06 Brigham And Women's Hospital System for diagnosis and treatment of wounds
US5134994A (en) 1990-02-12 1992-08-04 Say Sam L Field aspirator in a soft pack with externally mounted container
US5092858A (en) 1990-03-20 1992-03-03 Becton, Dickinson And Company Liquid gelling agent distributor device
US5149331A (en) 1991-05-03 1992-09-22 Ariel Ferdman Method and device for wound closure
US5278100A (en) 1991-11-08 1994-01-11 Micron Technology, Inc. Chemical vapor deposition technique for depositing titanium silicide on semiconductor wafers
US5645081A (en) 1991-11-14 1997-07-08 Wake Forest University Method of treating tissue damage and apparatus for same
US5636643A (en) 1991-11-14 1997-06-10 Wake Forest University Wound treatment employing reduced pressure
US5279550A (en) 1991-12-19 1994-01-18 Gish Biomedical, Inc. Orthopedic autotransfusion system
US5167613A (en) 1992-03-23 1992-12-01 The Kendall Company Composite vented wound dressing
FR2690617B1 (en) 1992-04-29 1994-06-24 Cbh Textile TRANSPARENT ADHESIVE DRESSING.
DE4306478A1 (en) 1993-03-02 1994-09-08 Wolfgang Dr Wagner Drainage device, in particular pleural drainage device, and drainage method
US5342376A (en) 1993-05-03 1994-08-30 Dermagraphics, Inc. Inserting device for a barbed tissue connector
US6241747B1 (en) 1993-05-03 2001-06-05 Quill Medical, Inc. Barbed Bodily tissue connector
US5344415A (en) 1993-06-15 1994-09-06 Deroyal Industries, Inc. Sterile system for dressing vascular access site
US5437651A (en) 1993-09-01 1995-08-01 Research Medical, Inc. Medical suction apparatus
US5549584A (en) 1994-02-14 1996-08-27 The Kendall Company Apparatus for removing fluid from a wound
US5556375A (en) 1994-06-16 1996-09-17 Hercules Incorporated Wound dressing having a fenestrated base layer
US5607388A (en) 1994-06-16 1997-03-04 Hercules Incorporated Multi-purpose wound dressing
US5664270A (en) 1994-07-19 1997-09-09 Kinetic Concepts, Inc. Patient interface system
DE29504378U1 (en) 1995-03-15 1995-09-14 Mtg Medizinisch Tech Geraeteba Electronically controlled low-vacuum pump for chest and wound drainage
US6234990B1 (en) * 1996-06-28 2001-05-22 Sontra Medical, Inc. Ultrasound enhancement of transdermal transport
US6135116A (en) 1997-07-28 2000-10-24 Kci Licensing, Inc. Therapeutic method for treating ulcers
GB9719520D0 (en) 1997-09-12 1997-11-19 Kci Medical Ltd Surgical drape and suction heads for wound treatment
AU755496B2 (en) 1997-09-12 2002-12-12 Kci Licensing, Inc. Surgical drape and suction head for wound treatment
DE19844355A1 (en) 1998-09-28 2000-04-06 Rainer E Sachse Adhesive wound dressing of flexible, membrane like material penetrable by air comprises integrated device which drains wound secretions or produces reduced pressure, or can be connected to an external suction system
US6488643B1 (en) 1998-10-08 2002-12-03 Kci Licensing, Inc. Wound healing foot wrap
US6287316B1 (en) 1999-03-26 2001-09-11 Ethicon, Inc. Knitted surgical mesh
US7799004B2 (en) 2001-03-05 2010-09-21 Kci Licensing, Inc. Negative pressure wound treatment apparatus and infection identification system and method
US6856821B2 (en) 2000-05-26 2005-02-15 Kci Licensing, Inc. System for combined transcutaneous blood gas monitoring and vacuum assisted wound closure
US6258075B1 (en) * 1999-04-08 2001-07-10 The Procter & Gamble Company Tampon with enhanced leakage protection
US6991643B2 (en) 2000-12-20 2006-01-31 Usgi Medical Inc. Multi-barbed device for retaining tissue in apposition and methods of use
EP1257313B1 (en) 2000-02-24 2004-05-12 Venetec International, Inc. Universal catheter anchoring system
GB0011202D0 (en) 2000-05-09 2000-06-28 Kci Licensing Inc Abdominal wound dressing
ATE407647T1 (en) 2000-05-22 2008-09-15 Arthur C Coffey WOUND DRESSING WITH SIS LAYER AND VACUUM CHAMBER
US6540705B2 (en) 2001-02-22 2003-04-01 Core Products International, Inc. Ankle brace providing upper and lower ankle adjustment
US7108683B2 (en) * 2001-04-30 2006-09-19 Kci Licensing, Inc Wound therapy and tissue management system and method with fluid differentiation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382441A (en) * 1978-12-06 1983-05-10 Svedman Paul Device for treating tissues, for example skin
US5678564A (en) * 1992-08-07 1997-10-21 Bristol Myers Squibb Liquid removal system
US6398767B1 (en) * 1997-05-27 2002-06-04 Wilhelm Fleischmann Process and device for application of active substances to a wound surface area
US6071267A (en) * 1998-02-06 2000-06-06 Kinetic Concepts, Inc. Medical patient fluid management interface system and method

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11141325B2 (en) 2006-09-28 2021-10-12 Smith & Nephew, Inc. Portable wound therapy system
US9227000B2 (en) 2006-09-28 2016-01-05 Smith & Nephew, Inc. Portable wound therapy system
US9642955B2 (en) 2006-09-28 2017-05-09 Smith & Nephew, Inc. Portable wound therapy system
US10130526B2 (en) 2006-09-28 2018-11-20 Smith & Nephew, Inc. Portable wound therapy system
US9956329B2 (en) 2008-03-07 2018-05-01 Smith & Nephew, Inc. Wound dressing port and associated wound dressing
US9033942B2 (en) 2008-03-07 2015-05-19 Smith & Nephew, Inc. Wound dressing port and associated wound dressing
US8702711B2 (en) 2008-12-30 2014-04-22 Kci Licensing, Inc. Reduced pressure augmentation of microfracture procedures for cartilage repair
EP2848268A1 (en) 2008-12-31 2015-03-18 KCI Licensing, Inc. Tissue roll scaffolds
US10155074B2 (en) 2008-12-31 2018-12-18 Kci Licensing, Inc. Tissue roll scaffolds
US10406036B2 (en) 2009-06-18 2019-09-10 Smith & Nephew, Inc. Apparatus for vacuum bridging and/or exudate collection
US11058588B2 (en) 2009-12-22 2021-07-13 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US10406037B2 (en) 2009-12-22 2019-09-10 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US9974695B2 (en) 2009-12-22 2018-05-22 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US9999547B2 (en) 2009-12-22 2018-06-19 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US9642750B2 (en) 2009-12-22 2017-05-09 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
USRE48117E1 (en) 2010-05-07 2020-07-28 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US9801761B2 (en) 2010-07-02 2017-10-31 Smith & Nephew Plc Provision of wound filler
US10537657B2 (en) 2010-11-25 2020-01-21 Smith & Nephew Plc Composition I-II and products and uses thereof
US11730876B2 (en) 2010-11-25 2023-08-22 Smith & Nephew Plc Composition I-II and products and uses thereof
US9956389B2 (en) 2010-12-22 2018-05-01 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
USD804014S1 (en) 2010-12-22 2017-11-28 Smith & Nephew, Inc. Suction adapter
US9050398B2 (en) 2010-12-22 2015-06-09 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US11247034B2 (en) 2010-12-22 2022-02-15 Smith & Nephew, Inc. Apparatuses and methods for negative pressure wound therapy
US11638666B2 (en) 2011-11-25 2023-05-02 Smith & Nephew Plc Composition, apparatus, kit and method and uses thereof
US11931226B2 (en) 2013-05-30 2024-03-19 Smith & Nephew Plc Wound dressing sealant and use thereof
WO2017119996A1 (en) * 2016-01-06 2017-07-13 Kci Liecensing, Inc. System and methods for the treatment of wounds with dressing having closed cells
EP3693034A1 (en) * 2016-01-06 2020-08-12 KCI Licensing, Inc. Systems and methods for the treatment of wounds with dressing having closed cells
US11318243B2 (en) 2016-01-06 2022-05-03 Kci Licensing, Inc. System and methods for the treatment of wounds with dressing having closed cells

Also Published As

Publication number Publication date
US7645269B2 (en) 2010-01-12
WO2008036162A3 (en) 2008-09-04
US20070038172A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
US7645269B2 (en) Gradient wound treatment system and method
EP1513478B1 (en) Wound therapy and tissue treatment management system and method with fluid differentiation
US20200315854A1 (en) Dressings, systems and methods for treating a tissue site
US10932953B2 (en) Reduced-pressure dressings, systems, and methods with evaporative devices
US6071267A (en) Medical patient fluid management interface system and method
AU2006290491B2 (en) Apparatus
AU2005235353B2 (en) Dressing and apparatus for cleansing the wounds
KR20080056208A (en) Apparatus with actives from tissue

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811537

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07811537

Country of ref document: EP

Kind code of ref document: A2